[{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Cancer immunotherapy,Cancer vaccine,Dendritic cells,Tumor immunity,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"J. F. Georges<sup>1<\/sup>, M. Zaher<sup>2<\/sup>, C. M. Mossop<sup>2<\/sup>, C. J. Bilbao<sup>2<\/sup>, C. M. Clay<sup>2<\/sup>, S. Amin<sup>2<\/sup>, H. A. Shaikh<sup>2<\/sup>, A. Trivedi<sup>3<\/sup>, W. Liu<sup>3<\/sup>, M. Namekar<sup>3<\/sup>, C. J. Hofferek<sup>3<\/sup>, K. Ernste<sup>3<\/sup>, E. H. Schumann<sup>4<\/sup>, M. Vu<sup>4<\/sup>, D. Oyewole-Said<sup>3<\/sup>, N. Bisht<sup>3<\/sup>, J. Vazquez-Perez<sup>3<\/sup>, A. M. Goralczyk<sup>2<\/sup>, L. Colman<sup>2<\/sup>, L. S. Kohler<sup>2<\/sup>, T. V. Cao<sup>2<\/sup>, N. Okereke<sup>2<\/sup>, B. L. Musher<sup>3<\/sup>, V. Ravi<sup>5<\/sup>, J. O. Kemnade<sup>6<\/sup>, R. C. Zvavanjanja<sup>4<\/sup>, J.-J. Zhu<sup>4<\/sup>, S. H. Hsu<sup>4<\/sup>, Y. Esquenazi-Levy<sup>4<\/sup>, N. Tandon<sup>4<\/sup>, A. Turtz<sup>2<\/sup>, <b>V. Konduri<\/b><sup>3<\/sup>, W. K. Decker<sup>3<\/sup>; <br\/><sup>1<\/sup>Banner University Medical Center Phoenix, Phoenix, AZ, <sup>2<\/sup>Cooper University Health, Camden, NJ, <sup>3<\/sup>Baylor College of Medicine, Houston, TX, <sup>4<\/sup>University of Texas Health Science Center, Houston, TX, <sup>5<\/sup>University of Texas MD Anderson Cancer Center, Houston, TX, <sup>6<\/sup>Infirmary Health, Mobile, AL","CSlideId":"","ControlKey":"ebf97532-6eac-412d-ad79-9bd23759ee24","ControlNumber":"10474","DisclosureBlock":"&nbsp;<b>J. F. Georges, <\/b> None..<br><b>M. Zaher, <\/b> None..<br><b>C. M. Mossop, <\/b> None..<br><b>C. J. Bilbao, <\/b> None..<br><b>C. M. Clay, <\/b> None..<br><b>S. Amin, <\/b> None..<br><b>H. A. Shaikh, <\/b> None..<br><b>A. Trivedi, <\/b> None..<br><b>W. Liu, <\/b> None..<br><b>M. Namekar, <\/b> None..<br><b>C. J. Hofferek, <\/b> None..<br><b>K. Ernste, <\/b> None..<br><b>E. H. Schumann, <\/b> None..<br><b>M. Vu, <\/b> None..<br><b>D. Oyewole-Said, <\/b> None..<br><b>N. Bisht, <\/b> None..<br><b>J. Vazquez-Perez, <\/b> None..<br><b>A. M. Goralczyk, <\/b> None..<br><b>L. Colman, <\/b> None..<br><b>L. S. Kohler, <\/b> None..<br><b>T. V. Cao, <\/b> None..<br><b>N. Okereke, <\/b> None.&nbsp;<br><b>B. L. Musher, <\/b> <br><b>Advisory\/consulting role with Celgene<\/b> Independent Contractor. <br><b>Advisory\/consulting role with Exelixis<\/b> Independent Contractor. <br><b>Speakers bureau relationship with Ipsen<\/b> Independent Contractor. <br><b>Research Funding from Lokon Pharma<\/b> Grant\/Contract. <br><b>V. Ravi, <\/b> <br><b>Clinical trial funding from Athenex<\/b> Grant\/Contract. <br><b>Clinical trial funding from Tracon<\/b> Grant\/Contract. <br><b>Clinical trial funding from Novartis<\/b> Grant\/Contract.<br><b>J. O. Kemnade, <\/b> None..<br><b>R. C. Zvavanjanja, <\/b> None..<br><b>J. Zhu, <\/b> None..<br><b>S. H. Hsu, <\/b> None..<br><b>Y. Esquenazi-Levy, <\/b> None.&nbsp;<br><b>N. Tandon, <\/b> <br><b>Ownership stake in BrainDynamics<\/b> Stock, Other Business Ownership. <br><b>Advisor and shareholder of Nervonik<\/b> Independent Contractor, Stock.<br><b>A. Turtz, <\/b> None.&nbsp;<br><b>V. Konduri, <\/b> <br><b>Ownership stake in Diakonos Oncology Corporation<\/b> Other Business Ownership, Patent. <br><b>W. K. Decker, <\/b> <br><b>Ownership stake in Diakonos Oncology Corporation<\/b> Other Business Ownership, Patent.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11436","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"1","PosterboardNumber":"1","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT093","PresenterBiography":null,"PresenterDisplayName":"Vanaja Konduri, PhD","PresenterKey":"043ba537-24a3-4ba5-9ce6-52d4bb808d71","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT093. Vaccine immunotherapy by homologous antigenic loading as adjuvant therapy for glioblastoma: Ongoing phase I analysis","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"610","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Vaccine immunotherapy by homologous antigenic loading as adjuvant therapy for glioblastoma: Ongoing phase I analysis","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Immunomodulation,Macrophages,Biomarkers,T cell,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Carlos Rodrigo Gil Del Alcazar<\/b><sup>1<\/sup>, Virginia Xu<sup>1<\/sup>, Chia-chi Lin<sup>2<\/sup>, Marta Gil-Martin<sup>3<\/sup>, Aung Naing<sup>4<\/sup>, Liqiong Fan<sup>1<\/sup>, Fang Yang<sup>1<\/sup>, David Quinn<sup>1<\/sup>, Jincheng Wu<sup>1<\/sup>, Cornelia Quadt<sup>5<\/sup>, Jennifer Mataraza<sup>1<\/sup><br><br\/><sup>1<\/sup>Novartis Biomedical Research, Cambridge, MA,<sup>2<\/sup>National Taiwan University Hospital, Taipei, Taiwan,<sup>3<\/sup>Catalan Institute of Oncology, Barcelona, Spain,<sup>4<\/sup>MD Anderson Cancer Center, Houston, TX,<sup>5<\/sup>Novartis Biomedical Research, Basel, Switzerland","CSlideId":"","ControlKey":"5fadef58-74b1-4944-9e48-538ce0d717b4","ControlNumber":"9540","DisclosureBlock":"<b>&nbsp;C. R. Gil Del Alcazar, <\/b> <br><b>Novartis<\/b> Employment. <br><b>V. Xu, <\/b> <br><b>Novartis<\/b> Employment.<br><b>C. Lin, <\/b> None..<br><b>M. Gil-Martin, <\/b> None..<br><b>A. Naing, <\/b> None.&nbsp;<br><b>L. Fan, <\/b> <br><b>Novartis<\/b> Employment. <br><b>F. Yang, <\/b> <br><b>Novartis<\/b> Employment. <br><b>D. Quinn, <\/b> <br><b>Novartis<\/b> Employment. <br><b>J. Wu, <\/b> <br><b>Novartis<\/b> Employment. <br><b>C. Quadt, <\/b> <br><b>Novartis<\/b> Employment. <br><b>J. Mataraza, <\/b> <br><b>Novartis<\/b> Employment.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11437","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"2","PosterboardNumber":"2","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT094","PresenterBiography":null,"PresenterDisplayName":"Carlos Gil Del Alcazar, PhD","PresenterKey":"2ffe0422-6462-4762-8101-c059f63040b9","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT094. Targeting CSF1R with BLZ945 results in effective peripheral and tumor immune microenvironment modulation in advanced solid tumors and may be associated with limited efficacy in recurrent non-mesenchymal glioblastoma","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"610","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Targeting CSF1R with BLZ945 results in effective peripheral and tumor immune microenvironment modulation in advanced solid tumors and may be associated with limited efficacy in recurrent non-mesenchymal glioblastoma","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Phase I,PD-L1,Biomarkers,Triple-negative breast cancer (TNBC),"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>C. Rojas<\/b><sup>1<\/sup>, B. Doger de Spéville<sup>2<\/sup>, S.-A. Im<sup>3<\/sup>, R. Shapira-Frommer<sup>4<\/sup>, M. De Miguel<sup>5<\/sup>, L. Cortijo<sup>6<\/sup>, M. Romeo Marin<sup>7<\/sup>, M. de Jonge<sup>8<\/sup>, M. Ayers<sup>9<\/sup>, Y. Zhang<sup>9<\/sup>, S. Zhai<sup>9<\/sup>, E. Chartash<sup>9<\/sup>, K. Dobrenkov<sup>9<\/sup>, J. Sohn<sup>10<\/sup>; <br\/><sup>1<\/sup>Centro de Investigacion Clinica, Bradford Hill, Recoleta, Santiago, RM, Chile, <sup>2<\/sup>START Madrid-FJD, Fundación Jiménez Díaz University Hospital, Madrid, Spain, <sup>3<\/sup>Seoul National University Hospital, Seoul National University College of Medicine, Cancer Research Institute, Seoul National University, Seoul, Korea, Republic of, <sup>4<\/sup>Ella Lemelbaum Institute for Immuno-Oncology, Sheba Medical Center, Ramat Gan, Israel, <sup>5<\/sup>START-Madrid CIOCC, Hosp. HM Sanchinarro, Madrid, Spain, <sup>6<\/sup>Hospital Universitario Quirónsalud, Madrid, Spain, <sup>7<\/sup>Institut Català d'Oncologia, Badalona, Spain, <sup>8<\/sup>Erasmus Medisch Centrum, Rotterdam, Netherlands, <sup>9<\/sup>Merck & Co., Inc., Rahway, NJ, <sup>10<\/sup>Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of","CSlideId":"","ControlKey":"6d762e71-d765-4939-8920-40e21a21c332","ControlNumber":"10475","DisclosureBlock":"<b>&nbsp;C. Rojas, <\/b> <br><b>MSD , BMS, Roche, AZ, Pfizer, Knight; Speaker’s bureau: MSD, BMS, Roche, AZ, Pfizer, Knight<\/b> Other, Consulting\/Advisory role. <br><b>BMS<\/b> Other, Travel\/Accommodations\/Expenses.<br><b>B. Doger de Spéville, <\/b> None.&nbsp;<br><b>S. Im, <\/b> <br><b>AstraZeneca, Pfize, Eisai, Roche, Daewoong Pharm, Boryung Pharm, Daiichi-Sankyo<\/b> Other, Research grant. <br><b>AstraZeneca, Novartis, Hanmi, Pfizer, Eisai, Roche, Lilly, GSK, MSD, Daiichi-Sankyo, Idience, Bertis<\/b> Other, Advisory\/Consultancy. <br><b>R. Shapira-Frommer, <\/b> <br><b>MSD, BMS, AstraZeneca, Novartis, Roche; Personal<\/b> Other, Honoraria\/Speaker. <br><b>MSD, Clovis Oncology, VBL Therapeutics.<\/b> Other, Fees\/Advisory Boards.<br><b>M. De Miguel, <\/b> None.&nbsp;<br><b>L. Cortijo, <\/b> <br><b>GSK<\/b> Other, Personal fees. <br><b>M. Romeo Marin, <\/b> <br><b>AstraZeneca<\/b> Other, Speaker. <br><b>GSK<\/b> Other, Advisory Board. <br><b>MSD<\/b> Other, Travel grants. <br><b>M. de Jonge, <\/b> <br><b>MSD<\/b> Other, Funding for this study to department. <br><b>M. Ayers, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Employment. <br><b>Merck & Co., Inc., Rahway, NJ, USA<\/b> Stock. <br><b>Y. Zhang, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Employment. <br><b>Merck & Co., Inc., Rahway, NJ, USA.<\/b> Stock. <br><b>S. Zhai, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Employment. <br><b>Merck & Co., Inc., Rahway, NJ, USA<\/b> Stock. <br><b>E. Chartash, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Employment. <br><b>Merck & Co., Inc., Rahway, NJ, USA<\/b> Stock. <br><b>K. Dobrenkov, <\/b> <br><b>Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA<\/b> Employment. <br><b>Merck & Co., Inc., Rahway, NJ, USA.<\/b> Stock. <br><b>J. Sohn, <\/b> <br><b>Seagen, MSD, Roche, Pfizer, Novartis, AstraZeneca, Lilly, GSK, Boehringer Ingelheim, Sanofi, Daiichi Sankyo, Qurient, Dragonfly, Eikon, Gilead, Celcuity<\/b> Other, Research Grant\/Funding (Institutional). <br><b>Bristol Myers Squibb, HLB Life Science, Sermonix, Olema, Hanmi, Ildong, Samyang<\/b> Other, Research Grant\/Funding (Institutional). <br><b>Daiichi Sankyo<\/b> Stock.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11438","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"3","PosterboardNumber":"3","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT095","PresenterBiography":null,"PresenterDisplayName":"Carlos Rojas, MD","PresenterKey":"177cd938-7c88-474e-ae83-3fb2c7659a59","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT095. Phase 1 evaluation of triple therapy with boserolimab (anti-CD27 agonist), pembrolizumab, and chemotherapy in patients with triple-negative breast cancer (TNBC) with PD-L1 combined positive score (CPS) &#60;10: Safety, antitumor activity, and association between biomarkers and response","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"610","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase 1 evaluation of triple therapy with boserolimab (anti-CD27 agonist), pembrolizumab, and chemotherapy in patients with triple-negative breast cancer (TNBC) with PD-L1 combined positive score (CPS) &#60;10: Safety, antitumor activity, and association between biomarkers and response","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Breast cancer,Immunotherapy,CAR T cells,MUC1,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>C. C. Bamdad<\/b><sup>1<\/sup>, J. E. Mortimer<sup>2<\/sup>, Y. Yuan<sup>3<\/sup>, J. M. Specht<sup>4<\/sup>, A. K. Stewart<sup>1<\/sup>, B. J. Smagghe<sup>1<\/sup>, S. C. Lin<sup>2<\/sup>, M. G. Carter<sup>1<\/sup>, T. W. Synold<sup>2<\/sup>, M. D. Fleming<sup>5<\/sup>, S. R. Hamilton<sup>2<\/sup>, V. Parekh<sup>2<\/sup>, D. M. Walkley<sup>1<\/sup>, Q. Liu-Michael<sup>2<\/sup>, K. R. Yi<sup>1<\/sup>, J.-L. S. Nash<sup>1<\/sup>, M. J. Nash<sup>1<\/sup>, S. J. Forman<sup>2<\/sup>; <br\/><sup>1<\/sup>Minerva Biotechnologies, Waltham, MA, <sup>2<\/sup>City of Hope, Duarte, CA, <sup>3<\/sup>Cedars-Sinai Medical Center, Los Angeles, CA, <sup>4<\/sup>Fred Hutchinson Cancer Center, Seattle, WA, <sup>5<\/sup>Boston Children's Hospital, Boston, MA","CSlideId":"","ControlKey":"665d2940-92b9-4cc9-84b5-c0ee54db1a4c","ControlNumber":"9623","DisclosureBlock":"&nbsp;<b>C. C. Bamdad, <\/b> None..<br><b>J. E. Mortimer, <\/b> None..<br><b>Y. Yuan, <\/b> None..<br><b>J. M. Specht, <\/b> None..<br><b>A. K. Stewart, <\/b> None..<br><b>B. J. Smagghe, <\/b> None..<br><b>S. C. Lin, <\/b> None..<br><b>M. G. Carter, <\/b> None..<br><b>T. W. Synold, <\/b> None..<br><b>M. D. Fleming, <\/b> None..<br><b>S. R. Hamilton, <\/b> None..<br><b>V. Parekh, <\/b> None..<br><b>D. M. Walkley, <\/b> None..<br><b>Q. Liu-Michael, <\/b> None..<br><b>K. R. Yi, <\/b> None..<br><b>J. S. Nash, <\/b> None..<br><b>M. J. Nash, <\/b> None..<br><b>S. J. Forman, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11439","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"4","PosterboardNumber":"4","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT096","PresenterBiography":null,"PresenterDisplayName":"Cynthia Bamdad, PhD","PresenterKey":"e3102614-4c15-47a4-91a0-67d8423eb124","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT096. Phase I first-in-human<b> <\/b>MUC1* targeted autologous CAR T cells for the treatment of metastatic breast cancers","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"610","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase I first-in-human<b> <\/b>MUC1* targeted autologous CAR T cells for the treatment of metastatic breast cancers","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"CTLA-4,Fc-engineered,dose escalation,solid tumors,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"S. Wang<sup>1<\/sup>, Q. Zheng<sup>1<\/sup>, Q. Gao<sup>2<\/sup>, Q. Zhang<sup>3<\/sup>, S. Wu<sup>4<\/sup>, Z. Li<sup>5<\/sup>, E. Li<sup>6<\/sup>, Q. Lu<sup>7<\/sup>, <b>F. Gan<\/b><sup>7<\/sup>, W. Tian<sup>7<\/sup>; <br\/><sup>1<\/sup>The Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China, <sup>2<\/sup>Immunotherapy Department, Henan Cancer Hospital, Zhengzhou, China, <sup>3<\/sup>Internal Medicine-Oncology Department, Harbin Medical University Cancer Hospital, Harbin, China, <sup>4<\/sup>Tumor Chemotherapy Department, Peking University First Hospital, Beijing, China, <sup>5<\/sup>Internal Medicine-Oncology Department, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China, <sup>6<\/sup>Internal Medicine-Oncology Department, The First Affiliated Hospital of Xi’an Jiaotong University, Xi'an, China, <sup>7<\/sup>ImmuneOnco Biopharmaceuticals (Shanghai) Inc., Shanghai, China","CSlideId":"","ControlKey":"500ac7fd-77e1-4ad8-8b7e-07eb645a92a8","ControlNumber":"9796","DisclosureBlock":"&nbsp;<b>S. Wang, <\/b> None..<br><b>Q. Zheng, <\/b> None..<br><b>Q. Gao, <\/b> None..<br><b>Q. Zhang, <\/b> None..<br><b>S. Wu, <\/b> None..<br><b>Z. Li, <\/b> None..<br><b>E. Li, <\/b> None.&nbsp;<br><b>Q. Lu, <\/b> <br><b>ImmuneOnco Biopharmaceuticals (Shanghai) Inc.<\/b> Employment. <br><b>F. Gan, <\/b> <br><b>ImmuneOnco Biopharmaceuticals (Shanghai) Inc.<\/b> Employment. <br><b>W. Tian, <\/b> <br><b>ImmuneOnco Biopharmaceuticals (Shanghai) Inc.<\/b> Employment.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11440","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"5","PosterboardNumber":"5","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT097","PresenterBiography":null,"PresenterDisplayName":"Frank Gan, PharmD","PresenterKey":"996fe941-4eab-402b-a8ed-8bc986ef3e32","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT097. IMM27M, a humanized Fc-engineered anti CTLA-4 antibody, in patients with advanced solid tumors: A phase I dose-escalation study","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"610","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"IMM27M, a humanized Fc-engineered anti CTLA-4 antibody, in patients with advanced solid tumors: A phase I dose-escalation study","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Antibody-drug conjugate (ADC),HER2,Intelligent ligase-dependent conjugation (iLDC) technology,Cancer therapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>C. Zhou<\/b><sup>1<\/sup>, B. Yang<sup>2<\/sup>, T. Deng<sup>3<\/sup>, B. Wang<sup>4<\/sup>, J. Zhang<sup>5<\/sup>, Y. Sun<sup>6<\/sup>, L. Wang<sup>7<\/sup>, H. Yang<sup>8<\/sup>, J. Wang<sup>9<\/sup>, W. Li<sup>1<\/sup>, Q. Song<sup>10<\/sup>, Y. Yang<sup>3<\/sup>; <br\/><sup>1<\/sup>Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine, shanghai, China, <sup>2<\/sup>Department of Medical Oncology, Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China, <sup>3<\/sup>Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China, <sup>4<\/sup>Department of Oncology, Fudan University Shanghai Cancer Center, shanghai, China, <sup>5<\/sup>Department of Phase I Clinical Trial Center, Fudan University Shanghai Cancer Center, shanghai, China, <sup>6<\/sup>Department of Phase I Clinical Trial Center,Shandong First Medical University Affiliated Tumor Hospital, Jinan, China, <sup>7<\/sup>Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, <sup>8<\/sup>Department of Breast Surgery, Suining Central Hospital, Suining, China, <sup>9<\/sup>Department II of breast, Linyi Cancer Hospital, Linyi, China, <sup>10<\/sup>Department of Oncology, the Fifth Medical Center, Chinese PLA General Hospital, Beijing, China","CSlideId":"","ControlKey":"ddd6d568-25d3-46d9-99ea-bf0bf29db658","ControlNumber":"9906","DisclosureBlock":"&nbsp;<b>C. Zhou, <\/b> None..<br><b>B. Yang, <\/b> None..<br><b>T. Deng, <\/b> None..<br><b>B. Wang, <\/b> None..<br><b>J. Zhang, <\/b> None..<br><b>Y. Sun, <\/b> None..<br><b>L. Wang, <\/b> None..<br><b>H. Yang, <\/b> None..<br><b>J. Wang, <\/b> None..<br><b>W. Li, <\/b> None..<br><b>Q. Song, <\/b> None..<br><b>Y. Yang, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11441","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"6","PosterboardNumber":"6","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT098","PresenterBiography":null,"PresenterDisplayName":"Caicun Zhou, PhD","PresenterKey":"49eea442-d77c-48ed-80ca-cb57b8f727ea","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT098. Phase I study of GQ1005, a new generation HER2-ADC, in patients with HER2-expressing and HER2 mutated advanced solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"610","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase I study of GQ1005, a new generation HER2-ADC, in patients with HER2-expressing and HER2 mutated advanced solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Immunotherapy,ILT2\/ILT4,PD-1,Novel anticancer agents,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. S. Wang<\/b><sup>1<\/sup>, M. R. Sharma<sup>2<\/sup>, W. J. Edenfield<sup>3<\/sup>, K. Sehgal<sup>4<\/sup>, D.-Y. Oh<sup>5<\/sup>, Y. Jiang<sup>6<\/sup>, J. Michalski<sup>7<\/sup>, J. Lee<sup>8<\/sup>, H. Hammers<sup>9<\/sup>, L.-Y. Bai<sup>10<\/sup>, C.-H. Hsu<sup>11<\/sup>, B. Dampier<sup>12<\/sup>, K. Zhou<sup>12<\/sup>, L. Yan<sup>12<\/sup>, L. K. Blum<sup>12<\/sup>, J. Sloan-Lancaster<sup>12<\/sup>, D. D. Kaplan<sup>12<\/sup>, D. Abhyankar<sup>12<\/sup>, H. D. Lieu<sup>12<\/sup>, V. Hanes<sup>12<\/sup>, A. Naing<sup>13<\/sup>; <br\/><sup>1<\/sup>Florida Cancer Specialists\/Sarah Cannon Research Institute, Sarasota, FL, <sup>2<\/sup>START Midwest, Grand Rapids, MI, <sup>3<\/sup>Prisma Health Cancer Institute, Greenville, SC, <sup>4<\/sup>Dana-Farber Cancer Institute, Boston, MA, <sup>5<\/sup>Seoul National University Hospital, Seoul, Korea, Republic of, <sup>6<\/sup>University of Maryland, Baltimore, MD, <sup>7<\/sup>Nebraska Cancer Specialists, Omaha, NE, <sup>8<\/sup>Samsung Medical Center, Seoul, Korea, Republic of, <sup>9<\/sup>UT Southwestern Medical Center, Dallas, TX, <sup>10<\/sup>China Medical University Hospital, Taichung City, Taiwan, <sup>11<\/sup>National Taiwan University Hospital, Taipei, Taiwan, <sup>12<\/sup>NGM Biopharmaceuticals, Inc., South San Francisco, CA, <sup>13<\/sup>MD Anderson Cancer Center, Houston, TX","CSlideId":"","ControlKey":"8258b158-10af-4e56-a1c6-d8403de2aa91","ControlNumber":"9561","DisclosureBlock":"<b>&nbsp;J. S. Wang, <\/b> <br><b>Stemline Therapeutics; Kanaph Therapeutics; Fusion Pharmaceuticals<\/b> Other, Consulting\/Advisory. <br><b>Eisai<\/b> Other, Speakers' Bureau. <br><b>Janssen Research & Development;<\/b> Other, Consulting\/Advisory, Research Funding to Institution. <br><b>AstraZeneca<\/b> Other, Speakers' Bureau, Research Funding to Institution. <br><b>NGM Biopharmaceuticals, Inc; Bicycle Therapeutics; BioNTech AG; Boehringer Ingelheim; Celgene; cyteir; Daiichi Sankyo; Genetech\/Roche; GlaxoSmithKline; H3 Biomedicine; Hutchinson MediPharma; Jacobio<\/b> Other, Research Funding to Institution. <br><b>Klus Pharma; Kymab; Loxo; LSK Bipartners; Macrogenics; Merck; Moderna Therapeutics; Phoenix Pharmaceuticals; Prelude Therapeutics; QiLu Pharmaceutical; Revolution Medicines; Ribon Therapeutics<\/b> Other, Research Funding to Institution. <br><b>Syndax; Taiho Pharmaceutical; Tesaro; TopAlliance BioSciences, Inc; Xencor; Artios; Erasca, Inc.; immuno-Gen; Cullinan Oncology; Immuno-Onc; Bayer Health; Biosplice; Zymeworks; BioTheryx; TeneoBio<\/b> Other, Research Funding to Institution. <br><b>Nurix; IgM Biosciences; PureTech; Forty Seven; Treadwell Therapeutics; MabSpace Biosciences; Novartis; Olema Oncology; Seven and Eight Biopharmaceuticals; ORIC Pharmaceuticals; Relay Therapeutics<\/b> Other, Research Funding to Institution. <br><b>Jazz Pharmaceuticals; Adagene; Agenus; Metabomed; BeiGene; Astellas Pharma; Blueprint Medicines; Hotspot Therapeutics; Centessa Pharmaceuticals; Allorion Therapeutics; C4 Therapeutics<\/b> Other, Research Funding to Institution. <br><b>M. R. Sharma, <\/b> <br><b>Abbott Laboratories; Lilly; Amgen; Moderna Therapeutics; Vertex; West Pharmaceutical<\/b> Stock. <br><b>Pliant Therapeutics<\/b> Other, Consulting\/Advisory. <br><b>NGM Biopharmaceuticals, Inc; AstraZeneca; Bolt Biotherapeutics; Compugen; Exelixis; Ikena; InhibRx; Jounce Therapeutics; KLUS Pharma; Loxo; Macrogenics; Symphogen; Syros Pharmaceuticals<\/b> Other, Research Funding to Institution. <br><b>Astellas Pharma; Celgene; Treadwell Therapeutics; EFFECTOR Therapeutics; Genmab; PureTech; GlaxoSmithKline\/Tesaro; Seagen; Shattuck Labs; Sapience Therapeutics; Tempest Therapeutics; Mersana<\/b> Other, Research Funding to Institution. <br><b>Onconova Therapeutics; Agenus; Alkermes; Alpine Immune Sciences; Seven and Eight Biopharmaceuticals; Cullinan Oncology; Debiopharm Group; Palleon Pharmaceuticals; Helsinn Therapeutics<\/b> Other, Research Funding to Institution. <br><b>Kinnate Biopharma; KSQ Therapeutics; SK Life Sciences; Theratechnologies; Tizona Therapeutics, Inc.; Boundless Bio Therapeutics; IgM Biosciences; Adcetrx Therapeutics; ALX Oncology; Artios<\/b> Other, Research Funding to Institution. <br><b>Black Diamond Therapeutics; Boehringer Ingelheim; Deciphera; Elevation Oncology; Incyte; Chugai Pharma; Mirati Therapeutics; Pliant; Qualigen Therapeutics; Repare Therapeutics<\/b> Other, Research Funding to Institution. <br><b>AbbVie; Bristol-Myers Squibb; Merck; Pfizer; Regeneron; Gilead Sciences; Johnson & Johnson\/Janssen;<\/b> Stock, Other, Research Funding to Institution.<br><b>W. J. Edenfield, <\/b> None.&nbsp;<br><b>K. Sehgal, <\/b> <br><b>Scholar Rock; Equinox Group, Inc; AmerisourceBergen; Exelixis, Inc; MedScape<\/b> Consulting\/Advisory. <br><b>Merck<\/b> Research Funding to Institution, Honoraria. <br><b>BinayTara Foundation; Pri-Med<\/b> Honoraria. <br><b>D. Oh, <\/b> <br><b>AstraZeneca; Novartis; Beigene; MSD<\/b> Other, Consulting\/Advisory, Research Grants. <br><b>Genentech\/Roche; Merck Serono; Bayer; Taiho; ASLAN; Halozyme; Zymeworks; BMS\/Celgene; Basilea; Turning Point; Yuhan; Arcus Biosciences; IQVIA; LG Chem; Astellas; Abbvie; J-Pharma; Mirati Therapeutics<\/b> Other, Consulting\/Advisory. <br><b>Eutilex<\/b> Other, Consulting\/Advisory. <br><b>Array; Eli Lilly; Servier; Handok<\/b> Other, Research Grants. <br><b>Y. Jiang, <\/b> <br><b>Humphries; Innovative Cellular Therapeutics; Cardinal Health<\/b> Other, Consulting.<br><b>J. Michalski, <\/b> None.&nbsp;<br><b>J. Lee, <\/b> <br><b>Astellas; AstraZeneca; Daiichi-Sankyo; Oncxerna; Transcenda; Mirati; Elevation Oncology; SDPO; Immudolon; Trutino Biosciences; Viracta Therapeutics<\/b> Other, Consulting\/Advisory. <br><b>MSD; SU2C-AACR<\/b> Other, Research Funding. <br><b>H. Hammers, <\/b> <br><b>Bristol-Myers Squibb<\/b> Travel, Other, Honoraria, Consulting\/Advisory, Research Funding to Institution. <br><b>Merck<\/b> Travel, Consulting\/Advisory, Research Funding to Institution. <br><b>Pfizer; Novartis; Lilly<\/b> Travel, Other, Consulting\/Advisory. <br><b>Exelixis; Bayer; ARMO BioSciences; Corvus Pharmaceuticals<\/b> Other, Consulting\/Advisory. <br><b>NGM Biopharmaceuticals, Inc; Aravive<\/b> Other, Research Funding to Institution. <br><b>Surface Oncology<\/b> Other, Consulting\/Advisory, Research Funding to Institution. <br><b>L. Bai, <\/b> <br><b>Eisai<\/b> Other, Drug support for investigator-initiated trial. <br><b>C. Hsu, <\/b> <br><b>AstraZeneca<\/b> Other, Consulting\/Advisory; Research Funding to Institution. <br><b>Bristol-Myers Squibb; Merck Sharpe & Dohme; Ono Pharmaceutical<\/b> Other, Consulting\/Advisory; Research Funding to Institution; Honoraria. <br><b>NGM Biopharmaceuticals, Inc; Bayer; Beigene; Eli Lilly; EMD Serono; Johnson & Johnson; NuCana; Genentech; Taiho; Ipsen<\/b> Other, Research Funding to Institution. <br><b>Roche<\/b> Travel, Other, Consulting\/Advisory; Research Funding to Institution; Honoraria. <br><b>Eisai<\/b> Other, Honoraria. <br><b>B. Dampier, <\/b> <br><b>NGM Biopharmaceuticals, Inc.<\/b> Employment, Stock, Stock Option, Travel. <br><b>K. Zhou, <\/b> <br><b>NGM Biopharmaceuticals, Inc.<\/b> Employment, Stock, Stock Option, Travel. <br><b>L. Yan, <\/b> <br><b>NGM Biopharmaceuticals, Inc.<\/b> Employment, Stock, Stock Option, Travel. <br><b>L. K. Blum, <\/b> <br><b>NGM Biopharmaceuticals, Inc<\/b> Employment, Stock, Stock Option, Travel, Patent. <br><b>J. Sloan-Lancaster, <\/b> <br><b>NGM Biopharmaceuticals, Inc<\/b> Employment, Stock, Stock Option, Travel. <br><b>D. D. Kaplan, <\/b> <br><b>NGM Biopharmaceuticals, Inc<\/b> Employment, Fiduciary Officer, Stock, Stock Option, Travel, Patent. <br><b>D. Abhyankar, <\/b> <br><b>NGM Biopharmaceuticals, Inc<\/b> Employment, Stock, Stock Option, Travel. <br><b>H. D. Lieu, <\/b> <br><b>NGM Biopharmaceuticals, Inc<\/b> Employment, Fiduciary Officer, Stock, Stock Option, Travel. <br><b>V. Hanes, <\/b> <br><b>NGM Biopharmaceuticals, Inc<\/b> Employment, Stock, Stock Option, Travel, Patent. <br><b>A. Naing, <\/b> <br><b>EMD Serono; MedImmune; Healios Onc. Nutrition; Atterocor\/Millendo; Amplimmune; Karyopharm Therapeutics; Incyte; Novartis; Regeneron; Bristol-Myers Squibb; Pfizer; Neon Therapeutics<\/b> Other, Research Funding. <br><b>Calithera Biosciences; TopAlliance Biosciences; Eli Lilly; Kymab; Arcus Biosciences; Surface Oncology; Monopteros Therapeutics; BioNTech SE; Seven & Eight Biopharma; SOTIO Biotech AG<\/b> Other, Research Funding. <br><b>Baxalta US Inc<\/b> Other, Research Funding to Spouse. <br><b>CTI; Deka Biosciences; Janssen Biotech; STCube Pharmaceuticals; OncoSec KEYNOTE-695; Genome & Company; Nouscom; Servier; Lynx Health; AbbVie<\/b> Other, Consulting\/Advisory. <br><b>Takeda; Pharming Healthcare Inc; Horizon Therapeutics USA, Inc<\/b> Other, Consulting\/Advisory (spouse). <br><b>NGM Biopharmaceuticals, Inc<\/b> Travel, Other, Consulting\/Advisory. <br><b>PsiOxus Therapeutics; Immune-Onc Therapeutics; CytomX Therapeutics; Merck Sharp & Dohme Corp<\/b> Consulting\/Advisory, Research Funding. <br><b>ARMO BioSciences; NeoImmuneTech<\/b> Travel, Research Funding. <br><b>AKH Inc; The Lynx Group; CME Outfitters; SITC; KSMO; Scripps Cancer Care Symposium; ASCO Direct Oncology Highlights; ESMO<\/b> Other, Honoraria.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11442","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"7","PosterboardNumber":"7","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT099","PresenterBiography":null,"PresenterDisplayName":"Judy Wang, MD","PresenterKey":"dd8c022a-de96-441f-a510-f2e0a4bd9a0c","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT099. NGM707 in combination with pembrolizumab in advanced or metastatic solid tumors: Preliminary results from dose escalation","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"610","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"NGM707 in combination with pembrolizumab in advanced or metastatic solid tumors: Preliminary results from dose escalation","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Cancer immunotherapy,Monoclonal antibodies,Circulating tumor DNA,Safety,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>B. A. Carneiro<\/b><sup>1<\/sup>, O. Gbolahan<sup>2<\/sup>, A. Abdul Razak<sup>3<\/sup>, J. F. Hilton<sup>4<\/sup>, A. Lambert<sup>5<\/sup>, J. Hood<sup>6<\/sup>, M. Pluta<sup>6<\/sup>, V. Bragulat<sup>6<\/sup>, E. Sanai<sup>6<\/sup>, R. Kumar<sup>7<\/sup>, D. Jodrell<sup>8<\/sup>, P. LoRusso<sup>9<\/sup>; <br\/><sup>1<\/sup>Legorreta Cancer Center, Brown University, and Lifespan Cancer Institute, Providence, RI, <sup>2<\/sup>Emory University, Atlanta, GA, <sup>3<\/sup>Princess Margaret Cancer Centre, Toronto, ON, Canada, <sup>4<\/sup>University of Ottawa, Ottawa, ON, Canada, <sup>5<\/sup>AstraZeneca, Waltham, MA, <sup>6<\/sup>AstraZeneca, Cambridge, United Kingdom, <sup>7<\/sup>AstraZeneca, Gaithersburg, MD, <sup>8<\/sup>University of Cambridge, Cambridge, United Kingdom, <sup>9<\/sup>Yale University Cancer Center, New Haven, CT","CSlideId":"","ControlKey":"9dbf6685-4e5a-4f7f-9277-41b65093c2d7","ControlNumber":"9884","DisclosureBlock":"<b>&nbsp;B. A. Carneiro, <\/b> <br><b>AbbVie<\/b> Other, Research funding. <br><b>Actuate Therapeutics<\/b> Other, Research funding. <br><b>Agenus<\/b> Other, Research funding. <br><b>Astellas<\/b> Other, Research funding. <br><b>AstraZeneca<\/b> Other, Research funding. <br><b>Bayer<\/b> Other, Research funding. <br><b>Dragonfly Therapeutics<\/b> Other, Research funding. <br><b>Mink Therapeutics<\/b> Other, Research funding. <br><b>Pfizer<\/b> Other, Research funding. <br><b>Pyxis Oncology<\/b> Other, Research funding. <br><b>Repare Therapeutics<\/b> Other, Research funding. <br><b>Regeneron<\/b> Other, Research funding. <br><b>Seattle Genetics<\/b> Other, Advisory board. <br><b>O. Gbolahan, <\/b> <br><b>AstraZeneca<\/b> Grant\/Contract. <br><b>A. Abdul Razak, <\/b> <br><b>AbbVie<\/b> Other, Trial support. <br><b>Adaptimmune<\/b> Other, Trial support; Advisory board. <br><b>Amgen<\/b> Other, Trial support. <br><b>AstraZeneca<\/b> Other, Trial support. <br><b>Blueprint Medicines<\/b> Other, Trial support. <br><b>Bristol Myers Squibb<\/b> Other, Trial support. <br><b>Daiichi Sankyo<\/b> Other, Trial support. <br><b>Deciphera Pharmaceuticals<\/b> Other, Trial support. <br><b>GlaxoSmithKline<\/b> Other, Trial support; Advisory board. <br><b>Iterion Therapeutics<\/b> Other, Trial support. <br><b>Karyopharm Therapeutics<\/b> Other, Trial support. <br><b>Merck<\/b> Other, Trial support. <br><b>Neoleukin Therapeutics<\/b> Other, Trial support. <br><b>Pfizer<\/b> Other, Trial support. <br><b>Rain Therapeutics<\/b> Other, Trial support. <br><b>Roche\/Genentech<\/b> Other, Trial support. <br><b>Symphogen<\/b> Other, Trial support. <br><b>Bayer<\/b> Other, Advisory board. <br><b>Inhibrx<\/b> Other, Advisory board. <br><b>Mediso<\/b> Other, Advisory board. <br><b>J. F. Hilton, <\/b> <br><b>AstraZeneca<\/b> Other, Advisory board. <br><b>Bristol Myers Squibb<\/b> Other, Advisory board. <br><b>Eli Lilly<\/b> Other, Advisory board. <br><b>Gilead<\/b> Other, Advisory board. <br><b>Merck<\/b> Other, Advisory board. <br><b>Novartis<\/b> Other, Advisory board. <br><b>Seattle Genetics<\/b> Other, Advisory board. <br><b>A. Lambert, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>J. Hood, <\/b> <br><b>AstraZeneca<\/b> Employment. <br><b>M. Pluta, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>V. Bragulat, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>E. Sanai, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>R. Kumar, <\/b> <br><b>AstraZeneca<\/b> Employment, Stock. <br><b>D. Jodrell, <\/b> <br><b>Ellipses Pharma Ltd<\/b> Independent Contractor. <br><b>Parexel<\/b> Independent Contractor. <br><b>Sentinel Oncology<\/b> Independent Contractor. <br><b>AstraZeneca<\/b> Other, Funding for clinical trials. <br><b>P. LoRusso, <\/b> <br><b>Abbvie;ABL Bio; Actuate Therapeutics;Agenus;AstraZeneca;Atreca Development;BAKX Therapeutics;Boehrigner Ingelheim;Compass;Cullinan Oncology;EMD Serono;GlaxoSmithKline;imCheck;IQVIA;Kineta Inc<\/b> Other, Advisory board. <br><b>Kyowa Kirin Pharmaceutical Development;MEKanistic;Mersana Therapeutics;Molecular Templates;NeuroTrials;Pfizer;Qualigen;Quanta Therapeutics;QED Therapeutics;Relay Therapeutics;Scenic Biotech<\/b> Other, Advisory board. <br><b>Schrödinger;Seagen;STCube Pharmaceuticals;Stemline;Takeda;Zentalis Pharmaceuticals<\/b> Other, Advisory board. <br><b>Roivant Sciences<\/b> Other, Consultant. <br><b>Roche-Genentech<\/b> Other, imCORE Alliance research network. <br><b>I-Mab<\/b> Other, Consultant; Advisory board. <br><b>Amgen<\/b> Other, Data monitoring committee. <br><b>DrenBio<\/b> Other, Data safety monitoring board. <br><b>SOTIO<\/b> Other, Consultant; Data monitoring committee.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11443","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"8","PosterboardNumber":"8","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT100","PresenterBiography":null,"PresenterDisplayName":"Jordan Best","PresenterKey":"09caff0e-0e82-4e63-92a0-4dbc38fa90bc","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT100. Safety and efficacy of AZD8853, an anti-growth and differentiation factor 15 (GDF15) antibody, in patients (pts) with advanced\/metastatic solid tumors: First-in-human study","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"610","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Safety and efficacy of AZD8853, an anti-growth and differentiation factor 15 (GDF15) antibody, in patients (pts) with advanced\/metastatic solid tumors: First-in-human study","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Wnt pathway,Small molecule drugs,Phase I,Solid tumors,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"N. Cook<sup>1<\/sup>, S. Blagden<sup>2<\/sup>, J. Lopez<sup>3<\/sup>, D. Sarker<sup>4<\/sup>, A. Greystoke<sup>5<\/sup>, N. Haris<sup>5<\/sup>, F. Kazmi<sup>2<\/sup>, K. Anam<sup>4<\/sup>, A. Ortego Franco<sup>1<\/sup>, R. Pihlak<sup>1<\/sup>, L. Goodwin<sup>6<\/sup>, D. Wilson<sup>6<\/sup>, C. Phillips<sup>6<\/sup>, J. Robertson<sup>6<\/sup>, H. Timmis<sup>6<\/sup>, C. Tilston<sup>6<\/sup>, <b>S. A. Woodcock<\/b><sup>6<\/sup>, R. Plummer<sup>5<\/sup>; <br\/><sup>1<\/sup>The University of Manchester and the Christie NHS Foundation Trust, Manchester, United Kingdom, <sup>2<\/sup>Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom, <sup>3<\/sup>Royal Marsden Hospital, London, United Kingdom, <sup>4<\/sup>King’s College London and Guy's Hospital, London, United Kingdom, <sup>5<\/sup>The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom, <sup>6<\/sup>Redx Pharma Plc, Manchester, United Kingdom","CSlideId":"","ControlKey":"34fb512f-a84c-45ee-ae23-e781e2671701","ControlNumber":"10691","DisclosureBlock":"&nbsp;<b>N. Cook, <\/b> None..<br><b>S. Blagden, <\/b> None..<br><b>J. Lopez, <\/b> None..<br><b>D. Sarker, <\/b> None..<br><b>A. Greystoke, <\/b> None..<br><b>N. Haris, <\/b> None..<br><b>F. Kazmi, <\/b> None..<br><b>K. Anam, <\/b> None..<br><b>A. Ortego Franco, <\/b> None..<br><b>R. Pihlak, <\/b> None.&nbsp;<br><b>L. Goodwin, <\/b> <br><b>Redx Pharma Plc<\/b> Independent Contractor. <br><b>D. Wilson, <\/b> <br><b>Redx Pharma Plc<\/b> Independent Contractor. <br><b>C. Phillips, <\/b> <br><b>Redx Pharma Plc<\/b> Employment, Stock Option. <br><b>J. Robertson, <\/b> <br><b>Redx Pharma Plc<\/b> Employment, Independent Contractor, Stock Option. <br><b>H. Timmis, <\/b> <br><b>Redx Pharma Plc<\/b> Employment, Stock Option. <br><b>C. Tilston, <\/b> <br><b>Redx Pharma Plc<\/b> Employment, Stock Option. <br><b>S. A. Woodcock, <\/b> <br><b>Redx Pharma Plc<\/b> Employment, Stock Option.<br><b>R. Plummer, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11444","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"9","PosterboardNumber":"9","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT101","PresenterBiography":null,"PresenterDisplayName":"Simon Woodcock, PhD","PresenterKey":"95df3e5e-3586-4f5e-80b0-f4e98d82902e","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT101. Final results of the first-in-human study of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with advanced solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"610","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Final results of the first-in-human study of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with advanced solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"5-Fluorouracil,Breast cancer,Capecitabine,Dihydropyrimidine dehydrogenase enzyme,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>D. Young<\/b><sup>1<\/sup>, S. Bigora<sup>1<\/sup>, M. Nyberg<sup>1<\/sup>, K. Parks<sup>1<\/sup>, A. Mahipar<sup>2<\/sup>, P. Boland<sup>3<\/sup>, E. Feldman<sup>4<\/sup>, H. Hochster<sup>3<\/sup>; <br\/><sup>1<\/sup>Processa Pharmaceuticals, Inc., Hanover, MD, <sup>2<\/sup>UH Cleveland Medical Center, Cleveland, OH, <sup>3<\/sup>Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, <sup>4<\/sup>Montefiore Medical Center, Bronx, NY","CSlideId":"","ControlKey":"b9913241-758f-4090-9105-664d09fd1e8c","ControlNumber":"10632","DisclosureBlock":"<b>&nbsp;D. Young, <\/b> <br><b>Processa Pharmaceuticals Inc<\/b> Employment, Fiduciary Officer, Stock, Patent. <br><b>S. Bigora, <\/b> <br><b>Processa Pharmaceuticals Inc<\/b> Employment, Fiduciary Officer, Stock, Patent. <br><b>M. Nyberg, <\/b> <br><b>Processa Phamaceuticals.com<\/b> Employment, Stock. <br><b>K. Parks, <\/b> <br><b>Processa Pharmaceuticals Inc<\/b> Employment, Stock.<br><b>A. Mahipar, <\/b> None..<br><b>P. Boland, <\/b> None..<br><b>E. Feldman, <\/b> None..<br><b>H. Hochster, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11446","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"10","PosterboardNumber":"11","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT103","PresenterBiography":null,"PresenterDisplayName":"David Young, PhD;Pharm D","PresenterKey":"e199f50a-5bd6-4a2b-803c-583fc92102c2","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT103. Next generation capecitabine (NGC-Cap) in phase 1b trial significantly increases 5-FU exposure while improving safety profile compared to capecitabine","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"610","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Next generation capecitabine (NGC-Cap) in phase 1b trial significantly increases 5-FU exposure while improving safety profile compared to capecitabine","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Novel anticancer agents,Pembrolizumab,Solid tumors,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>L. L. Siu<\/b><sup>1<\/sup>, M. Gil-Martin<sup>2<\/sup>, B. Chul Cho<sup>3<\/sup>, R. Perets<sup>4<\/sup>, J. Hilton<sup>5<\/sup>, R. Geva<sup>6<\/sup>, I. Lugowska<sup>7<\/sup>, M. Gutierrez<sup>8<\/sup>, M. Bonomi<sup>9<\/sup>, R. Dziadziuszko<sup>10<\/sup>, D. Rasco<sup>11<\/sup>, E. Ben-Ami<sup>12<\/sup>, C. P. Rodriguez<sup>13<\/sup>, S. Siddiqi<sup>14<\/sup>, N. Myer<sup>14<\/sup>, L. Suttner<sup>14<\/sup>, D. Wilson<sup>14<\/sup>, O. O. Akala<sup>14<\/sup>, M. de Miguel<sup>15<\/sup>; <br\/><sup>1<\/sup>Princess Margaret Cancer Centre, Toronto, ON, Canada, <sup>2<\/sup>Catalan Institute of Oncology- IDIBELL L’Hospitalet, Barcelona, Spain, <sup>3<\/sup>Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of, <sup>4<\/sup>Rambam Health Care Campus and Technion - Israel Institute of Technology, Haifa, Israel, <sup>5<\/sup>Ottawa Hospital Cancer Centre, Ottawa, ON, Canada, <sup>6<\/sup>Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, <sup>7<\/sup>Maria Sklodowska Curie Institute of Oncology, Warsaw, Poland, <sup>8<\/sup>Hackensack Meridian Health, Hackensack, NJ, <sup>9<\/sup>The Ohio State University Wexner Medical, Columbus, OH, <sup>10<\/sup>Medical University of Gdansk, Gdansk, Poland, <sup>11<\/sup>The START Center for Cancer Care, San Antonio, TX, <sup>12<\/sup>Sheba Medical Center, Tel Aviv, Israel, <sup>13<\/sup>University of Washington, Seattle, WA, <sup>14<\/sup>Merck & Co., Inc., Rahway, NJ, <sup>15<\/sup>START-Madrid CIOCC HM Sanchinarro, Madrid, Spain","CSlideId":"","ControlKey":"6164f794-6dae-4c18-83f9-982619fd8b84","ControlNumber":"10426","DisclosureBlock":"<b>&nbsp;L. L. Siu, <\/b> <br><b>Merck, Pfizer, AstraZeneca, Roche, GlaxoSmithKline, Voronoi, Arvinas, Navire, Relay, Daiichi Sankyo, Amgen, Marengo, Medicenna, Tubulis, LTZ Therapeutics, Pangea<\/b> Other, Advisory Board. <br><b>Novartis, Bristol-Myers Squibb, Pfizer, Boerhinger-Ingelheim, GlaxoSmithKline, Roche\/Genentech, AstraZeneca, Merck, Celgene, Astellas, Bayer, Abbvie, Amgen, Mirati, BioNTech, 23Me, EMD Serono<\/b> Other, Sponsor\/Funding. <br><b>Agios<\/b> Stock, Other, Spouse. <br><b>Treadwell Therapeutics<\/b> Other, Ownership Interest (Spouse). <br><b>M. Gil-Martin, <\/b> <br><b>GSK<\/b> Travel, Other, Speakers Bureau; Scientific meeting expenses. <br><b>MSD<\/b> Travel, Other, Speakers Bureau; Scientific meeting expenses. <br><b>Astra-Zeneca<\/b> Other, Scientific meeting expenses. <br><b>B. Chul Cho, <\/b> <br><b>Champions Oncology, Crown Bioscience, Imagen, PearlRiver Bio GmbH, Bristol Myers Squibb<\/b> Other, Royalties (PDX, PDO, PDC Licensing Contract - not patent). <br><b>MOGAM Institute, LG Chem, Oscotec, Interpark Bio Convergence Corp, Gradiant Bioconvergence, Therapex,  GIInnovation, GI-Cell, Abion, Abbvie, AstraZeneca, Bayer, Blueprint Medicines<\/b> Other, Research Grant. <br><b>Boehringer Ingelheim, Champions Onoclogy, CJ bioscience, CJ Blossom Park, Cyrus, Dizal Pharma, Genexine, Janssen, Lilly, MSD, Novartis, Nuvalent, Oncternal, Ono, Regeneron, Dong-A ST<\/b> Other, Research Grant. <br><b>Bridgebio therapeutics, Yuhan, ImmuneOncia, Illumina, Kanaph therapeutics, JINTSbio, Hanmi, CHA Bundang Medical Center, Daewoong Pharmaceutical Co., Ltd., Vertical Bio AG<\/b> Other, Research Grant. <br><b>Korea Institute of Oriental Medicine, National Research Foundation of Korea, KHIDI<\/b> Other, Research Grant. <br><b>Abion, BeiGene, Novartis, AstraZeneca, Boehringer-Ingelheim, Roche, BMS, CJ, CureLogen, Cyrus therapeutics, Ono, Onegene Biotechnology<\/b> Other, Consultant. <br><b>Abion, BeiGene, Novartis, AstraZeneca, Boehringer-Ingelheim, Roche, BMS, CJ, CureLogen, Cyrus therapeutics, Ono, Onegene Biotechnology, Yuhan, Pfizer, Eli Lilly<\/b> Other, Consultant. <br><b>GI-Cell, Guardant, HK Inno-N, Imnewrun Biosciences Inc.,  Janssen, Takeda, MSD, Medpacto, Blueprint medicines, RandBio, Hanmi, GC Cell, Gilead, Ridgeline Discovery GmbH<\/b> Other, Consultant. <br><b>Yonsei University Health System<\/b> Employment, Other, Affiliate. <br><b>KANAPH Therapeutic Inc, Bridgebio therapeutics, Cyrus therapeutics, Guardant Health, Oscotec Inc, J INTS Bio, Therapex Co., Ltd, Gilead, Amgen, AstraZeneca, Regeneron, Seagen, Samsung Bioepis<\/b> Other, Advisory Board. <br><b>ASCO, AstraZeneca, Guardant, Roche, ESMO, IASLC, Korean Cancer Association, Korean Society of Medical Onoclogy, Korean Society of Thyroid-Head and Neck Surgery<\/b> Other, Invited Speaker. <br><b>Korean Cancer Study Group, Novartis, MSD, The Chinese Thoracic Oncology Society, Pfizer, Liangyihui Network Technology Co., Ltd.<\/b> Other, Invited Speaker. <br><b>TheraCanVac Inc, Gencurix Inc, Bridgebio therapeutics, KANAPH Therapeutic Inc, Cyrus therapeutics, Interpark Bio Convergence Corp., J INTS BIO<\/b> Stock. <br><b>J INTS BIO<\/b> Other, Member of the board of Directors. <br><b>DAAN Biotherapeutics<\/b> Other, Founder. <br><b>R. Perets, <\/b> <br><b>1E Therapeutics.<\/b> Grant\/Contract, Other, Research Grant, Advisory Role. <br><b>Clexio, Galmed Therapeutics, Gilboa Therapeutics<\/b> Other, Advisory Role. <br><b>Abbvie, Sanofi, Astra-Zeneca, Biomica, BMS, Regeneron, Biond Biologics, Genentech, Gilead<\/b> Other, Principal Investigator. <br><b>J. Hilton, <\/b> <br><b>BMS, AstraZeneca, Novartis, Lilly, Merck, Gilead, Seattle Genetics<\/b> Other, Advisory. <br><b>R. Geva, <\/b> <br><b>Roche, MSD, Merck, Medison, Janssen, Pfizer,  AstraZeneca, Amgen, Takeda, Novartis<\/b> Other, Honoraria. <br><b>Astrazeneca, BOL Pharma, Roche, Bayer, MSD, Oncotest, Pfizer<\/b> Other, Advisory\/Consultancy. <br><b>Pyxis<\/b> Stock, Other, Medical Lead. <br><b>Medison, Merck<\/b> Travel. <br><b>I. Lugowska, <\/b> <br><b>ROCHE, BMS, BI, JANSSEM, Revolution, Affimed, MSD, Pfizer. TESARO, Agenus, Astra<\/b> Other, Research Grant, Principal Investigator. <br><b>M. Gutierrez, <\/b> <br><b>Incyte, Sanofi, BI<\/b> Other, Advisory Board. <br><b>Guardant<\/b> Other, Consultant. <br><b>COTA\/OMI<\/b> Stock.<br><b>M. Bonomi, <\/b> None.&nbsp;<br><b>R. Dziadziuszko, <\/b> <br><b>Roche<\/b> Other, Invited Speaker, Advisory Board, Principal Investigator, Advisory Role. <br><b>MSD, Novartis, Bristol-Meyers Squibb<\/b> Other, Principal Investigator. <br><b>Pfizer<\/b> Other, Invited Speaker, Advisory Board, Principal Investigator. <br><b>AstraZeneca<\/b> Other, Invited Speaker, Advisory Board, Principal Investigator. <br><b>D. Rasco, <\/b> <br><b>Merck<\/b> Other, Principal Investigator.<br><b>E. Ben-Ami, <\/b> None.&nbsp;<br><b>C. P. Rodriguez, <\/b> <br><b>Adaptimmune, Eisai, Vaccitech, Cue Biopharma, Coherus,<\/b> Other, Advisory Role. <br><b>Pionyr<\/b> Other, DSMC. <br><b>S. Siddiqi, <\/b> <br><b>Merck & Co., Inc.<\/b> Employment. <br><b>N. Myer, <\/b> <br><b>Merck & Co., Inc.<\/b> Employment. <br><b>L. Suttner, <\/b> <br><b>Merck & Co., Inc.<\/b> Employment, Stock. <br><b>D. Wilson, <\/b> <br><b>Merck & Co., Inc.<\/b> Employment. <br><b>O. O. Akala, <\/b> <br><b>Merck & Co., Inc.<\/b> Employment, Stock, Other, Project Lead.<br><b>M. de Miguel, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11447","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"11","PosterboardNumber":"12","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT104","PresenterBiography":null,"PresenterDisplayName":"Lillian Siu, MD","PresenterKey":"7501fbfb-af2e-4490-8f84-1f5ea25999e8","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT104. Results from a phase 1 study of the anti-immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 plus pembrolizumab in patients with previously treated advanced solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"610","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Results from a phase 1 study of the anti-immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 plus pembrolizumab in patients with previously treated advanced solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++PL03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Pancreatic cancer,Gastrointestinal cancers: pancreatic,Phase I,Colorectal,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Tariq Arshad<\/b><sup>1<\/sup>, Stephen Neidle<sup>2<\/sup>, Sreenivasa Chandana<sup>3<\/sup>, Erkut Borazanci<sup>4<\/sup><br><br\/><sup>1<\/sup>Qualigen Therapeutics, San Ramon, CA,<sup>2<\/sup>University College of London, London, United Kingdom,<sup>3<\/sup>START MidWest, Grand Rapids, MI,<sup>4<\/sup>Honor Health, Scottsdale, AZ","CSlideId":"","ControlKey":"055d754e-3c24-44d6-adec-f034524a34c1","ControlNumber":"10700","DisclosureBlock":"<b>&nbsp;T. Arshad, <\/b> <br><b>Qualigen Therapeutics<\/b> Employment. <br><b>S. Neidle, <\/b> <br><b>Qualigen Therapeutics<\/b> Other, Consultant.<br><b>S. Chandana, <\/b> None..<br><b>E. Borazanci, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11448","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"12","PosterboardNumber":"13","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT105","PresenterBiography":null,"PresenterDisplayName":"Tariq Arshad, MBA;MD","PresenterKey":"187913a9-74b7-49f5-b78f-34a784f32147","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT105. Early clinical experience with a novel first-in-class G-quadruplex experimental anti-cancer drug","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"610","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Early clinical experience with a novel first-in-class G-quadruplex experimental anti-cancer drug","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Pancreatic cancer,Paclitaxel,Targeted drug delivery,Combination therapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"C. Pilgrim<sup>1<\/sup>, M. Smith<sup>2<\/sup>, E.-J. Ban<sup>2<\/sup>, S. Ellis<sup>2<\/sup>, J. Zalcberg<sup>1<\/sup>, B. Markman<sup>2<\/sup>, M. Lashof-Sullivan<sup>3<\/sup>, <b>L. Indolfi<\/b><sup>3<\/sup>; <br\/><sup>1<\/sup>School of Public Health and Preventative Medicine, Monash University and Alfred Health, Melbourne, Australia, <sup>2<\/sup>The Alfred Hospital, Melbourne, Australia, <sup>3<\/sup>PanTher Therapeutics, Austin, TX","CSlideId":"","ControlKey":"3c1853fa-71e8-4a21-b3ce-94f7718ee6bb","ControlNumber":"9505","DisclosureBlock":"&nbsp;<b>C. Pilgrim, <\/b> None..<br><b>M. Smith, <\/b> None..<br><b>E. Ban, <\/b> None..<br><b>S. Ellis, <\/b> None.&nbsp;<br><b>J. Zalcberg, <\/b> <br><b>Biomarin<\/b> Stock Option. <br><b>Opthea<\/b> Stock Option. <br><b>Amarin<\/b> Stock Option. <br><b>Concert Pharmaceutical<\/b> Stock Option. <br><b>Frequency Therapeutics<\/b> Stock Option. <br><b>Gilead<\/b> Stock Option. <br><b>Madrigal Pharmaceuticals<\/b> Stock Option. <br><b>UniQure<\/b> Stock Option. <br><b>Zogogenix<\/b> Stock Option. <br><b>Orphazyme<\/b> Stock Option. <br><b>Moderna Therapeutics<\/b> Stock Option. <br><b>TWST<\/b> Stock Option. <br><b>Novavax<\/b> Stock Option. <br><b>Teladoc<\/b> Stock Option. <br><b>MSD Oncology<\/b> Travel. <br><b>ICON Group<\/b> Travel. <br><b>PRAXIS<\/b> Travel.<br><b>B. Markman, <\/b> None..<br><b>M. Lashof-Sullivan, <\/b> None..<br><b>L. Indolfi, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11449","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"13","PosterboardNumber":"14","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT106","PresenterBiography":null,"PresenterDisplayName":"Laura Indolfi, PhD","PresenterKey":"7a5bb734-9ae2-4ed4-9196-45efba234eca","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT106. First-in-human phase 1 study of paclitaxel-eluting PTM-101 film in subjects with borderline resectable or locally advanced pancreatic cancers","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"610","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"First-in-human phase 1 study of paclitaxel-eluting PTM-101 film in subjects with borderline resectable or locally advanced pancreatic cancers","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Immunotherapy,Kirsten rat sarcoma (KRAS),Pancreatic ductal adenocarcinoma (PDAC),Colorectal cancer (CRC),"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>J. R. Perry<\/b>, H. VanWyk, A. M. Tavares, T. Kheoh, E. Welkowsky, C. M. Haqq, P. C. DeMuth, L. K. McNeil; <br\/>Elicio Therapeutics, Boston, MA","CSlideId":"","ControlKey":"ef278ad5-f3e9-4391-a5cd-16977c7f250e","ControlNumber":"10448","DisclosureBlock":"<b>&nbsp;J. R. Perry, <\/b> <br><b>Elicio Therapeutics<\/b> Employment, Stock Option. <br><b>H. VanWyk, <\/b> <br><b>Elicio Therapeutics<\/b> Employment, Stock Option. <br><b>A. M. Tavares, <\/b> <br><b>Elicio Therapeutics<\/b> Employment, Stock Option. <br><b>T. Kheoh, <\/b> <br><b>Elicio Therapeutics<\/b> Employment, Stock Option. <br><b>E. Welkowsky, <\/b> <br><b>Elicio Therapeutics<\/b> Employment, Stock Option. <br><b>C. M. Haqq, <\/b> <br><b>Elicio Therapeutics<\/b> Employment, Stock Option. <br><b>P. C. DeMuth, <\/b> <br><b>Elicio Therapeutics<\/b> Employment, Stock Option. <br><b>L. K. McNeil, <\/b> <br><b>Elicio Therapeutics<\/b> Employment, Stock Option.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11450","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"14","PosterboardNumber":"15","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT107","PresenterBiography":null,"PresenterDisplayName":"Peter DeMuth, PhD","PresenterKey":"302ea8a7-81ba-4e65-b1bb-802504d4a48d","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT107. Durable immunogenicity of ELI-002 2P in AMPLIFY-201: Lymph node targeted mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"610","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Durable immunogenicity of ELI-002 2P in AMPLIFY-201: Lymph node targeted mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Peptides,Prostate cancer,Vaccines,T cell,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"W. Lilleby<sup>1<\/sup>, A. Bergqvist<sup>2<\/sup>, A. Nasi<sup>3<\/sup>, W. Rasch<sup>2<\/sup>, <b>S. Mangsbo<\/b><sup>4<\/sup>; <br\/><sup>1<\/sup>Oslo University Hospital, Oslo, Norway, <sup>2<\/sup>Ultimovacs, Oslo, Norway, <sup>3<\/sup>Ultimovacs, Uppsala, Sweden, <sup>4<\/sup>Uppsala University, Uppsala, Sweden","CSlideId":"","ControlKey":"82436abc-9781-45cf-9396-c053b023dfb4","ControlNumber":"9801","DisclosureBlock":"<b>&nbsp;W. Lilleby, <\/b> <br><b>Ultimovacs<\/b> Grant\/Contract. <br><b>A. Bergqvist, <\/b> <br><b>Ultimovacs<\/b> Employment, Stock. <br><b>A. Nasi, <\/b> <br><b>AstraZeneca<\/b> Other, Disclaimer, currently employed by AstraZeneca, but the work presented is not related to that employment. <br><b>W. Rasch, <\/b> <br><b>Ultimovacs<\/b> Employment, Stock. <br><b>S. Mangsbo, <\/b> <br><b>Ultimovacs<\/b> Employment, Stock, Grant\/Contract, Patent. <br><b>Strike pharma<\/b> Stock, Grant\/Contract, Patent. <br><b>Immuneed<\/b> Stock.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11451","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"15","PosterboardNumber":"16","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT108","PresenterBiography":null,"PresenterDisplayName":"Sara Mangsbo, PhD","PresenterKey":"f98d8d6c-a710-42a6-93f5-3def342797fd","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT108. Phase I data from TENDU101, a first-in-human trial of a novel synthetic peptide conjugate cancer vaccine platform assessed in recurrent prostate cancer patients before salvage treatment","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"610","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase I data from TENDU101, a first-in-human trial of a novel synthetic peptide conjugate cancer vaccine platform assessed in recurrent prostate cancer patients before salvage treatment","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Advanced cancer,Antibody,Antitumor activity,TGF-&#946;,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>I. Rodriguez Rivera<\/b><sup>1<\/sup>, D. Sommerhalder<sup>1<\/sup>, M. Sahtout<sup>2<\/sup>, C. Ferlini<sup>2<\/sup>, D. Ngo<sup>2<\/sup>, S. Jha<sup>2<\/sup>, J. Engelhardt<sup>2<\/sup>, A. Tolcher<sup>1<\/sup>; <br\/><sup>1<\/sup>NEXT Oncology, San Antonio, TX, <sup>2<\/sup>AbbVie Inc., North Chicago, IL","CSlideId":"","ControlKey":"6e7fbbc3-1f90-432a-9e8a-4177934196fb","ControlNumber":"9896","DisclosureBlock":"<b>&nbsp;I. Rodriguez Rivera, <\/b> <br><b>Texas Oncology<\/b> Employment, Stock. <br><b>NEXT Oncology<\/b> Stock. <br><b>Syneos<\/b> Other, Honoraria. <br><b>Werewolf Therapeutics<\/b> Other, Consulting fees. <br><b>Amgen, BeiGene, Boundless Bio, EMD Serono Research and Development Institute \/ Merck, Flare Therapeutics, Navire Pharma, NextPoint Therapeutics, Omega Therapeutics, Revolution Medicines<\/b> Other, Ongoing or past research funding for studies. <br><b>Suzhou Transcenta Therapeutics, Vincerx Pharma, Werewolf Therapeutics<\/b> Other, Ongoing or past research funding for studies. <br><b>D. Sommerhalder, <\/b> <br><b>Texas Oncology<\/b> Employment, Stock. <br><b>NEXT Oncology<\/b> Stock. <br><b>Syneos<\/b> Other, Honoraria. <br><b>Guidepoint<\/b> Other, Consulting fees. <br><b>AbbVie, ADC Therapeutics, Ascentage Pharma Group, Astellas, Biomea Fusion, Boehringer Ingelheim, BJ Bioscience, BioNTech, Fate Therapeutics, Gilead Sciences, Haihe Pharmaceutical, IconOVir Bio<\/b> Other, Ongoing or past research funding for studies. <br><b>Immuneering, Impact Therapeutics, Kura Oncology, MediLink Therapeutics, Mirati Therapeutics, Monopteros Therapeutics, Navire Pharma Inc, Nimbus Saturn Inc, NGM Biopharmaceuticals, OncoResponse Inc<\/b> Other, Ongoing or past research funding for studies. <br><b>Parthenon, Pfizer, Revolution Medicines, Symphogen, Tachyon Therapeutics, Teon Therapeutics, Vincerx Pharma, ZielBio Inc<\/b> Other, Ongoing or past research funding for studies. <br><b>M. Sahtout, <\/b> <br><b>AbbVie Inc.<\/b> Employment, Stock, May own stock. <br><b>C. Ferlini, <\/b> <br><b>AbbVie Inc.<\/b> Employment, Stock, May own stock. <br><b>D. Ngo, <\/b> <br><b>AbbVie Inc.<\/b> Employment, Stock, May own stock. <br><b>S. Jha, <\/b> <br><b>AbbVie Inc.<\/b> Employment, Stock, May own stock. <br><b>J. Engelhardt, <\/b> <br><b>AbbVie Inc.<\/b> Employment, Stock, May own stock. <br><b>A. Tolcher, <\/b> <br><b>AbbVie Inc., Aclaris Therapeutics, Agenus Inc., Asana BioSciences, AxImmune, Bayer, BluPrint Oncology, Daiichi Sankyo Inc., Gilde Healthcare Partners, HBM Partners, IDEA Pharma, Immuneering<\/b> Other, Consultant. <br><b>ImmunoMet Therapeutics, Inc., IMPACT Therapeutics US, Inc., Karma Oncology, Kirilys Therapeutics, Inc., Lengo Therapeutics, Inc., Link Immunotherapeutics, MEKanistic Therapeutics, Menarini Ricerche,<\/b> Other, Consultant. <br><b>Mersana, Nanobiotix, Novo Nordisk Inc., Nerviano Medical Sciences S.r.I. (NMS), Nurix Therapeutics, Ocellaris Pharma, Inc. and Eli Lilly, Partner Therapeutics, Pfizer Inc., Qualigen Therapeutics,<\/b> Other, Consultant. <br><b>Pierre Fabre, Roche, Ryvu Therapeutics, Seattle Genetics, SK Life Science, SOTIO Biotechnology Co., Spirea Limited Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd,<\/b> Other, Consultant. <br><b>Transcenta Therapeutics Inc., Transgene, Trillium Therapeutics Inc., Verastem Oncology, VRise Therapeutics Inc., Zentalis Pharmaceuticals<\/b> Other, Consultant. <br><b>Adagene Inc., Aro Biotherapeutics, BioInvent, Boehringer Ingelheim International GmbH, Bright Peak Therapeutics, Deka Biosciences, Eleven Bio, Elucida, EMD Serono\/Merck KGaA, HiberCell Inc.,<\/b> Other, Advisory boards. <br><b>Ikena Oncology, Immunome, Janssen Global Services LLC, Mirati, NBE Therapeutics, Pelican, Jazz, Pieris Pharma, Pyxis Oncology, Roche, Senti Biosciences, Vincerx, ZielBio Inc.,<\/b> Other, Advisory boards. <br><b>Zymeworks Biopharmaceuticals Inc.<\/b> Other, Advisory boards. <br><b>New Experimental Therapeutics, LLC d\/b\/a NEXT Oncology<\/b> Other, fees for consulting and advisory board memberships for Dr Anthony Tolcher are paid to New Experimental Therapeutics, LLC d\/b\/a NEXT Oncology, of which he is president and founder.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11452","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"16","PosterboardNumber":"17","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT109","PresenterBiography":null,"PresenterDisplayName":"Sravya Kotaru","PresenterKey":"5184e197-4f0b-45d2-b52d-bc8e2056e801","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT109. Livmoniplimab and budigalimab combination therapy in treating patients with metastatic ovarian granulosa cell tumors: Results from dose escalation in a first-in-human study","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"610","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Livmoniplimab and budigalimab combination therapy in treating patients with metastatic ovarian granulosa cell tumors: Results from dose escalation in a first-in-human study","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Ovarian cancer,Myc Amplification,RNA Splicing Mutations,Small molecule inhibitor,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>N. Yamamoto<\/b><sup>1<\/sup>, T. Koyama<sup>1<\/sup>, Y. Katsuya<sup>1<\/sup>, J. Sato<sup>1<\/sup>, T. Shimizu<sup>2<\/sup>, Y. Tanoue<sup>3<\/sup>, M. Yamamoto<sup>3<\/sup>, H. Tozaki<sup>3<\/sup>, E. Takahara<sup>3<\/sup>, S. Shoji<sup>3<\/sup>, A. Mizutani<sup>3<\/sup>, D. Morishita<sup>3<\/sup>, R. W. Oda<sup>3<\/sup>, H. Miyake<sup>3<\/sup>, K. Yonemori<sup>1<\/sup>; <br\/><sup>1<\/sup>National Cancer Center Hospital, Tokyo, Japan, <sup>2<\/sup>Wakayama Medical University, Wakayama, Japan, <sup>3<\/sup>Chordia Therapeutics Inc., Kanagawa, Japan","CSlideId":"","ControlKey":"3dded69e-6257-4fa2-b01c-676f0e1be08b","ControlNumber":"9515","DisclosureBlock":"<b>&nbsp;N. Yamamoto, <\/b> <br><b>AbbVie; Astellas; AstraZeneca; Bayer; BMS; Boehringer Ingelheim; Carna Biosciences; Chiome Bioscience; Chugai; CMIC; Daiichi-Sankyo; Eisai; Eli Lilly; Genmab; GlaxoSmithKline; InventisBio<\/b> Grant\/Contract. <br><b>Janssen Pharma; KAKEN; Kyowa Kirin; Merck, Merck Sharp & Dohme; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Rakuten Medical; Shionogi; Sumitomo Pharma; Taiho; Takeda; Toray<\/b> Grant\/Contract. <br><b>T. Koyama, <\/b> <br><b>AstraZeneca; Chugai; Sysmex<\/b> Other, Honoraria. <br><b>AstraZeneca; Chugai; Daiichi-Sankyo; Eli Lilly; Novartis; PACT Pharma; Takeda; Zymworks<\/b> Grant\/Contract.<br><b>Y. Katsuya, <\/b> None.&nbsp;<br><b>J. Sato, <\/b> <br><b>AstraZeneca; Chugai; Eisai; Fujifilm<\/b> Other, Honoraria. <br><b>Amgen<\/b> Other, Advisory Role. <br><b>T. Shimizu, <\/b> <br><b>AbbVie; Chordia Therapeutics; Chugai; Kyowa Kirin<\/b> Other, Advisor. <br><b>3D-Medicine; AbbVie; Astellas Pharma; AstraZeneca; Bristol- Myers Squibb; Chordia Therapeutics; Daiichi-Sankyo; Eisai; Eli Lilly; Five Prime; Incyte; LOXO Oncology; Novartis; Pfizer; PharmaMar<\/b> Grant\/Contract. <br><b>Symbio Pharmaceuticals; Takeda Oncology<\/b> Grant\/Contract. <br><b>Chugai; Eli Lilly; IQVIA; MSD; Taiho<\/b> Other, Honoraria. <br><b>Y. Tanoue, <\/b> <br><b>Chordia Therapeutics<\/b> Employment, Stock Option. <br><b>M. Yamamoto, <\/b> <br><b>Chordia Therapeutics<\/b> Employment, Stock Option. <br><b>H. Tozaki, <\/b> <br><b>Chordia Therapeutics<\/b> Employment, Stock, Stock Option, Patent. <br><b>Honda Motor<\/b> Stock. <br><b>E. Takahara, <\/b> <br><b>Chordia Therapeutics<\/b> Employment. <br><b>S. Shoji, <\/b> <br><b>Chordia Therapeutics<\/b> Employment, Stock Option. <br><b>A. Mizutani, <\/b> <br><b>Chordia Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>D. Morishita, <\/b> <br><b>Chordia Therapeutics<\/b> Employment, Stock, Stock Option, Patent. <br><b>R. W. Oda, <\/b> <br><b>Chordia Therapeutics<\/b> Employment, Stock Option. <br><b>Takeda<\/b> Stock. <br><b>H. Miyake, <\/b> <br><b>Chordia Therapeutics<\/b> Employment, Stock, Stock Option, Other, Representative Director. <br><b>Takeda<\/b> Stock. <br><b>K. Yonemori, <\/b> <br><b>AstraZeneca; Boeringer Ingelheim; Chugai; Daiichi-Sankyo; Eisai; Eli Lilly; Genmab; Haihe; Kyowa Kirin; MSD; Merk Biopharma; Nihon Kayaku; Novartis; Ono; Pfizer; Sanofi; Seagen; Taiho; Takeda<\/b> Grant\/Contract. <br><b>AstraZeneca; Bayer; Boeringer Ingelheim; Chugai; Daiichi-Sankyo; Eisai; Eli Lilly; Fujifilm Pharma; Janssen; MSD; Ono; PDR Pharma; Pfizer; Sanofi; Takeda<\/b> Other, Honoraria. <br><b>AstraZeneca; Eisai; Genmab; Gliad; Henlius; MSD; Novartis; OncXerna; Sanofi; Takeda<\/b> Other, Advisory Board.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11453","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"17","PosterboardNumber":"18","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT110","PresenterBiography":null,"PresenterDisplayName":"Noboru Yamamoto, MD, PhD","PresenterKey":"e300de95-cb82-4f53-9f33-abe56cdd0635","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT110. A first-in-human phase I study of CTX-712 in patients with advanced, relapsed or refractory malignant tumors (CTX-712-CL-01 study): Efficacy and safety in solid tumor cohorts","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"610","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A first-in-human phase I study of CTX-712 in patients with advanced, relapsed or refractory malignant tumors (CTX-712-CL-01 study): Efficacy and safety in solid tumor cohorts","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Phase I,Heat shock factor 1 pathway,GCN2,ARID1A mutation,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"S. Pacey<sup>1<\/sup>, C. Leung<sup>1<\/sup>, S. Rodney<sup>2<\/sup>, A. Filipa Palma DosReis<sup>1<\/sup>, R. Ruddle<sup>3<\/sup>, M. Tall<sup>3<\/sup>, K. Swales<sup>3<\/sup>, R. te Poele<sup>3<\/sup>, P. Workman<sup>3<\/sup>, D. Marsolini<sup>4<\/sup>, M. Sardone<sup>4<\/sup>, E. Poradosu<sup>4<\/sup>, S. Shemesh<sup>5<\/sup>, <b>U. Banerji<\/b><sup>6<\/sup>; <br\/><sup>1<\/sup>University of Cambridge Addenbrookes Hospital, Cambridge, United Kingdom, <sup>2<\/sup>The Institute of Cancer Research and The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom, <sup>3<\/sup>The Institute of Cancer Research, London, United Kingdom, <sup>4<\/sup>Nuvectis Pharma, Inc., Fort Lee, NJ, <sup>5<\/sup>Nuvectis Pharma, Fort Lee, NJ, <sup>6<\/sup>The Institute of Cancer Research and and The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom","CSlideId":"","ControlKey":"4ef84422-0401-4802-ab1c-2a8d461e3e33","ControlNumber":"9911","DisclosureBlock":"<b>&nbsp;S. Pacey, <\/b> <br><b>Astra Zeneca<\/b> Grant\/Contract. <br><b>Janssen<\/b> Grant\/Contract. <br><b>Guardant Health<\/b> Grant\/Contract.<br><b>C. Leung, <\/b> None..<br><b>S. Rodney, <\/b> None..<br><b>A. Filipa Palma DosReis, <\/b> None.&nbsp;<br><b>R. Ruddle, <\/b> <br><b>The Institute of Cancer Research<\/b> Employment. <br><b>M. Tall, <\/b> <br><b>The Institute of Cancer Research<\/b> Employment. <br><b>Nuvectis Pharma Inc<\/b> Grant\/Contract, PD analysis on Nuvectis Pharma Inc sponsored clinical trials. <br><b>K. Swales, <\/b> <br><b>The Institute of Cancer Research<\/b> Employment. <br><b>Nuvectis Pharma Inc<\/b> Grant\/Contract, PD analysis on Nuvectis Pharma Inc sponsored clinical trials. <br><b>Astra Zeneca AB<\/b> Grant\/Contract, PD analysis on AstraZeneca AB sponsored clinical trial. <br><b>Menarini Ricerche S.p.A<\/b> Grant\/Contract, PD analysis on Menarini Ricerche S.p.A sponsored clinical trial. <br><b>Stemline Therapeutics Inc<\/b> Grant\/Contract, PD analysis on Stemline Therapeutics Inc sponsored clinical trial.<br><b>R. te Poele, <\/b> None.&nbsp;<br><b>P. Workman, <\/b> <br><b>The Institute of Cancer Research<\/b> Employment. <br><b>STORM Therapeutics<\/b> Employment, Fiduciary Officer, Stock Option. <br><b>Alterome Therapeutics<\/b> Independent Contractor, Stock Option. <br><b>Astex Therapeutics<\/b> Independent Contractor, Grant\/Contract. <br><b>Black Diamond Therapeutics<\/b> Independent Contractor, Stock Option. <br><b>CHARM Therapeutics<\/b> Independent Contractor, Stock Option. <br><b>EPICOMBI.AI LTD<\/b> Independent Contractor, Stock Option. <br><b>MerckKGaA<\/b> Independent Contractor, Grant\/Contract. <br><b>NextechInvest<\/b> Independent Contractor, Stock Option. <br><b>Nuvectis Pharma<\/b> Independent Contractor, Stock Option, Grant\/Contract. <br><b>Vividion<\/b> Independent Contractor. <br><b>CV6 Therapeutics<\/b> Other, Scientific adviser - no payment received. <br><b>AstraZeneca<\/b> Other, Member of Pension Scheme. <br><b>Chemical Probes Portal<\/b> Other, Executive Director - non-profit research resource, no funding received. <br><b>Vivan Therapeutics<\/b> Other, Research collaboration no research funding received. <br><b>D. Marsolini, <\/b> <br><b>Nuvectis Pharma, Inc.<\/b> Employment. <br><b>M. Sardone, <\/b> <br><b>Nuvectis Pharma, Inc.<\/b> Employment, Stock. <br><b>E. Poradosu, <\/b> <br><b>Nuvectis Pharma, Inc.<\/b> Employment, Stock, Stock Option. <br><b>S. Shemesh, <\/b> <br><b>Nuvectis Pharma, Inc.<\/b> Employment. <br><b>U. Banerji, <\/b> <br><b>The Institute of Cancer Research<\/b> Employment. <br><b>Phoenix Solutions<\/b> Other, Advisory board. <br><b>PharmEnable<\/b> Other, Advisory board. <br><b>Ellipses<\/b> Other, Advisory board. <br><b>Astra Zeneca<\/b> Other, Research funding. <br><b>Onyx<\/b> Other, Research funding. <br><b>Chugai Pharma<\/b> Other, Research funding. <br><b>BTG<\/b> Other, Research funding. <br><b>Verastem Oncology<\/b> Other, Research funding. <br><b>Nuvectis Pharma Inc<\/b> Grant\/Contract, PD analysis on Nuvectis Pharma Inc sponsored clinical trials.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11454","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"18","PosterboardNumber":"19","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT111","PresenterBiography":null,"PresenterDisplayName":"Udai Banerji, MD;PhD","PresenterKey":"65fbff29-a51b-4389-a28d-e9e5c403aaeb","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT111. Pharmacokinetic and pharmacodynamic evaluation of NXP800, a novel GCN2 activator, in a first in human clinical trial","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"610","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Pharmacokinetic and pharmacodynamic evaluation of NXP800, a novel GCN2 activator, in a first in human clinical trial","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Cancer vaccine,GITR,PD-1,Head and neck squamous cell carcinoma,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Rom S. Leidner<\/b><sup>1<\/sup>, Christopher Paustian<sup>1<\/sup>, Shawn  M.  Jensen<sup>1<\/sup>, Tarsem Moudgil<sup>1<\/sup>, Yoshinobu Koguchi<sup>1<\/sup>, Noah Simons<sup>1<\/sup>, Venkatesh Rajamanickam<sup>1<\/sup>, Ryan Meng<sup>1<\/sup>, Marcus A. Couey<sup>2<\/sup>, Quyen Vu<sup>1<\/sup>, Matthew H. Taylor<sup>1<\/sup>, Anne Long<sup>1<\/sup>, abigail J. Staeck<sup>1<\/sup>, Lakhvir Kaur<sup>1<\/sup>, Tijana Jovanovic<sup>1<\/sup>, Brady Bernard<sup>1<\/sup>, Tanisha Christie<sup>1<\/sup>, Noriko Iwamoto<sup>3<\/sup>, yuriko minegishi<sup>4<\/sup>, Koji Ueda<sup>4<\/sup>, William Redmond<sup>1<\/sup>, Lessli M. Rushforth<sup>1<\/sup>, Takashi Shimada<sup>3<\/sup>, Patrick Rethwisch<sup>1<\/sup>, Ashish Patel<sup>1<\/sup>, Richard  B.  Bell<sup>1<\/sup>, Carlo B. Bifulco<sup>1<\/sup>, Traci L. Hilton<sup>5<\/sup>, Hong-Ming Hu<sup>5<\/sup>, Brian Piening<sup>1<\/sup>, Walter J. Urba<sup>1<\/sup>, Bernard A. Fox<sup>1<\/sup><br><br\/><sup>1<\/sup>Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR,<sup>2<\/sup>Boston University, Boston, MA,<sup>3<\/sup>Shimadzu Corporation, Kyoto, Japan,<sup>4<\/sup>Japanese Foundation for Cancer Research, Tokyo, Japan,<sup>5<\/sup>UbiVac, Portland, OR","CSlideId":"","ControlKey":"bb71917a-15a2-423e-bdc2-b5d29dc9fd66","ControlNumber":"10563","DisclosureBlock":"<b>&nbsp;R. S. Leidner, <\/b> <br><b>Bristol Myers Squibb<\/b> Grant\/Contract, Travel. <br><b>Incyte<\/b> Grant\/Contract. <br><b>AstraZeneca<\/b> Grant\/Contract. <br><b>Merck<\/b> Other, Advisory. <br><b>Vir<\/b> Other, Advisory. <br><b>CDR-Life<\/b> Other, Advisory.<br><b>C. Paustian, <\/b> None..<br><b>S. M. Jensen, <\/b> None..<br><b>T. Moudgil, <\/b> None.&nbsp;<br><b>Y. Koguchi, <\/b> <br><b>BMS<\/b> Grant\/Contract. <br><b>Shimadzu<\/b> Grant\/Contract. <br><b>GSK<\/b> Grant\/Contract.<br><b>N. Simons, <\/b> None..<br><b>V. Rajamanickam, <\/b> None..<br><b>R. Meng, <\/b> None..<br><b>M. A. Couey, <\/b> None..<br><b>Q. Vu, <\/b> None.&nbsp;<br><b>M. H. Taylor, <\/b> <br><b>Bristol-Myers Squibb, Eisai, Merck, Agenus Bio, Moderna, Pfizer, ISA Therapeutics, Immune-Onc, and Simcha.<\/b> Grant\/Contract. <br><b>Bristol Myers Squibb<\/b> Other, Speakers' bureau, consulting , SAB. <br><b>Eisai Inc<\/b> Other, Speakers' burea, consulting , SABu. <br><b>Blueprint Medicines<\/b> Other, Speakers' bureau. <br><b>Merck<\/b> Other, Speakers' bureau, consulting , SAB. <br><b>Pfizer<\/b> Other, Consulting\/advisory board member:. <br><b>Bayer<\/b> Other, Consulting\/advisory board member:. <br><b>Sanofi\/Genzyme<\/b> Other, Consulting\/advisory board member:. <br><b>Regeneron<\/b> Other, Consulting\/advisory board member:. <br><b>Blueprint Medicines<\/b> Other, Consulting\/advisory board member:. <br><b>Immune-onc<\/b> Other, Consulting\/advisory board member:. <br><b>Exelixis<\/b> Other, Consulting\/advisory board member:. <br><b>Cascade Prodrug<\/b> Other, Consulting\/advisory board member:.<br><b>A. Long, <\/b> None..<br><b>A. J. Staeck, <\/b> None..<br><b>L. Kaur, <\/b> None..<br><b>T. Jovanovic, <\/b> None..<br><b>B. Bernard, <\/b> None..<br><b>T. Christie, <\/b> None.&nbsp;<br><b>N. Iwamoto, <\/b> <br><b>Shimadzu Corporation<\/b> Employment.<br><b>Y. minegishi, <\/b> None..<br><b>K. Ueda, <\/b> None.&nbsp;<br><b>W. Redmond, <\/b> <br><b>Bristol-Myers Squibb<\/b> Grant\/Contract. <br><b>MiNA Therapeutics<\/b> Grant\/Contract. <br><b>Inhibrx<\/b> Grant\/Contract. <br><b>Veana Therapeutics<\/b> Grant\/Contract. <br><b>Shimadzu<\/b> Grant\/Contract. <br><b>Galecto<\/b> Grant\/Contract. <br><b>CanWell Pharma<\/b> Grant\/Contract. <br><b>Galectin Therapeutic<\/b> Other Intellectual Property, Patents\/Licensing fees. <br><b>Vesselon<\/b> Other, SAB. <br><b>Medicenna<\/b> Other, SAB. <br><b>Veana Therapeutics<\/b> Other, SAB.<br><b>L. M. Rushforth, <\/b> None.&nbsp;<br><b>T. Shimada, <\/b> <br><b>Shimadzu Corporation<\/b> Employment.<br><b>P. Rethwisch, <\/b> None..<br><b>A. Patel, <\/b> None.&nbsp;<br><b>R. B. Bell, <\/b> <br><b>Merck<\/b> Other, Ad board, speakers bureau. <br><b>BMS<\/b> Grant\/Contract. <br><b>EMD Serono<\/b> Other, Ad board. <br><b>Bright Peak<\/b> Other, Consultant. <br><b>C. B. Bifulco, <\/b> <br><b>PrimeVax<\/b> Stock, Other, Scientific Advisory Board & Stock Ownership:. <br><b>BioAI<\/b> Stock, Other, Scientific Advisory Board & Stock Ownership:. <br><b>Lunaphore<\/b> Other, SAB. <br><b>Sanofi<\/b> Other, consultant. <br><b>Agilent<\/b> Other, consultant. <br><b>Roche<\/b> Other, consultant. <br><b>Incendia<\/b> Other, consultant. <br><b>Illumina<\/b> Grant\/Contract. <br><b>T. L. Hilton, <\/b> <br><b>UbiVac<\/b> Employment. <br><b>H. Hu, <\/b> <br><b>UbiVac<\/b> Stock, Other, Co-Founder, CSO. <br><b>Immuxell<\/b> Employment, Stock, Other, Founder, CSO. <br><b>B. Piening, <\/b> <br><b>Illumina<\/b> Grant\/Contract. <br><b>Shimadzu Scientific<\/b> Grant\/Contract. <br><b>Loxo@Lilly<\/b> Other, Consulting. <br><b>W. J. Urba, <\/b> <br><b>AsraZeneca<\/b> Other, DSMB. <br><b>B. A. Fox, <\/b> <br><b>Akoya<\/b> Grant\/Contract. <br><b>Bristol Myers Squibb<\/b> Grant\/Contract, Travel. <br><b>Calidi<\/b> Travel, Other, SAB - honorarium. <br><b>Hookipa<\/b> Other, Consultant - fees. <br><b>Incyte<\/b> Grant\/Contract, Travel. <br><b>Pfizer<\/b> Other, SAB - honorarium. <br><b>PrimeVax<\/b> Stock Option, Other, Board of Directors. <br><b>Turnstone<\/b> Stock Option, Travel, SAB - honoraria. <br><b>Shimadzu<\/b> Grant\/Contract. <br><b>UbiVac<\/b> Stock, Patent, Cofounder, CEO, and Board of Directors. <br><b>Viralytics\/Merck<\/b> Grant\/Contract, Other, SAB.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11455","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"19","PosterboardNumber":"20","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT112","PresenterBiography":null,"PresenterDisplayName":"Rom Leidner, MD","PresenterKey":"8d70d02b-032d-4510-ad02-28f2b55239a1","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT112. An off-the-shelf multivalent vaccine containing cancer&#8217;s dark matter, DPV-001, combined with PD-1 +\/- GITR in head &#38; neck cancer: safety, efficacy, and immunodynamics from the phase 1 GITRVax trial","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"610","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"An off-the-shelf multivalent vaccine containing cancer&#8217;s dark matter, DPV-001, combined with PD-1 +\/- GITR in head &#38; neck cancer: safety, efficacy, and immunodynamics from the phase 1 GITRVax trial","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Anti-PD-1,,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>H.-Q. Mai<\/b><sup>1<\/sup>, Y.-Q. Han<sup>2<\/sup>, G.-W. Wu<sup>3<\/sup>, K.-Y. Yang<sup>4<\/sup>, C.-B. Chen<sup>5<\/sup>, M. Wang<sup>6<\/sup>, X.-M. Luo<sup>6<\/sup>, S.-H. Wei<sup>6<\/sup>, X. Tan<sup>6<\/sup>, P. Xue<sup>6<\/sup>, R.-H. Xu<sup>1<\/sup>; <br\/><sup>1<\/sup>Sun Yat-sen University Cancer Center, Guangzhou, China, <sup>2<\/sup>Hunan Cancer Hospital, Changsha, China, <sup>3<\/sup>Meizhou People's Hospital, Meizhou, China, <sup>4<\/sup>Union Hospital, Cancer Center, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, <sup>5<\/sup>Fujian Cancer Hospital, Fuzhou, China, <sup>6<\/sup>Shanghai Junshi Bioscience Co., Ltd, Shanghai, China","CSlideId":"","ControlKey":"e51d17a3-22b0-41ad-b0c6-ed1e62385afe","ControlNumber":"9591","DisclosureBlock":"&nbsp;<b>H. Mai, <\/b> None..<br><b>Y. Han, <\/b> None..<br><b>G. Wu, <\/b> None..<br><b>K. Yang, <\/b> None..<br><b>C. Chen, <\/b> None.&nbsp;<br><b>M. Wang, <\/b> <br><b>Shanghai Junshi Bioscience Co., Ltd<\/b> Employment. <br><b>X. Luo, <\/b> <br><b>Shanghai Junshi Bioscience Co., Ltd<\/b> Employment. <br><b>S. Wei, <\/b> <br><b>Shanghai Junshi Bioscience Co., Ltd<\/b> Employment. <br><b>X. Tan, <\/b> <br><b>Shanghai Junshi Bioscience Co., Ltd<\/b> Employment. <br><b>P. Xue, <\/b> <br><b>Shanghai Junshi Bioscience Co., Ltd<\/b> Employment. <br><b>R. Xu, <\/b> <br><b>Bristol-Myers Squibb.<\/b> Other, Consulting or Advisory Role. <br><b>Merck Serono<\/b> Other, Consulting or Advisory Role. <br><b>Roche<\/b> Other, Consulting or Advisory Role. <br><b>Astellas<\/b> Other, Consulting or Advisory Role. <br><b>AstraZeneca<\/b> Other, Consulting or Advisory Role.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11456","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"20","PosterboardNumber":"21","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT113","PresenterBiography":null,"PresenterDisplayName":"Wei Su","PresenterKey":"672bd65f-83ad-4d9d-9d21-9cfacfa181a3","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT113. A dose-exploring, randomized, open-label, Phase I study for toripalimab subcutaneous injection in patients with advanced nasopharyngeal carcinoma","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"610","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A dose-exploring, randomized, open-label, Phase I study for toripalimab subcutaneous injection in patients with advanced nasopharyngeal carcinoma","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Novel anticancer agents,Pembrolizumab,Head and neck squamous cell carcinoma,Lung cancer: non-small cell,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>B. Cho<\/b><sup>1<\/sup>, J. Hilton<sup>2<\/sup>, C. P. Rodriguez<sup>3<\/sup>, M. Bonomi<sup>4<\/sup>, L. L. Siu<sup>5<\/sup>, M. Gil-Martin<sup>6<\/sup>, S. Siddiqi<sup>7<\/sup>, N. M. Myer<sup>7<\/sup>, L. Suttner<sup>7<\/sup>, D. Wilson<sup>7<\/sup>, O. Akala<sup>7<\/sup>, R. Dziadziuszko<sup>8<\/sup>; <br\/><sup>1<\/sup>Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea, Republic of, <sup>2<\/sup>Ottawa Hospital Cancer Centre, Ottawa, ON, Canada, <sup>3<\/sup>University of Washington, Seattle, WA, <sup>4<\/sup>The Ohio State University Wexner Medical Center, Columbus, OH, <sup>5<\/sup>Princess Margaret Cancer Center, University of Toronto, Toronto, ON, Canada, <sup>6<\/sup>Catalan Institute of Oncology-IDIBELL L’Hospitalet, Barcelona, Spain, <sup>7<\/sup>Merck & Co., Inc., Rahway, NJ, <sup>8<\/sup>Medical University of Gdansk, Gdansk, Poland","CSlideId":"","ControlKey":"922690ca-160c-4271-be2b-e3e31328f38d","ControlNumber":"10307","DisclosureBlock":"<b>&nbsp;B. Cho, <\/b> <br><b>Champions Oncology, Crown Bioscience, Imagen, PearlRiver Bio GmbH, Bristol Myers Squibb<\/b> Other, Royalties (PDX, PDO, PDC Licensing Contract- not patent). <br><b>MOGAM Institute, LG Chem, Oscotec, Interpark Bio Convergence Corp, Gradiant Bioconvergence, Therapex,  GIInnovation, GI-Cell, Abion, Abbvie, AstraZeneca, Bayer, Blueprint Medicines<\/b> Grant\/Contract. <br><b>Boehringer Ingelheim, Champions Onoclogy, CJ bioscience, CJ Blossom Park, Cyrus, Dizal Pharma, Genexine, Janssen, Lilly, MSD, Novartis, Nuvalent, Oncternal, Ono, Regeneron, Dong-A ST<\/b> Grant\/Contract. <br><b>Bridgebio therapeutics, Yuhan, ImmuneOncia, Illumina, Kanaph therapeutics, JINTSbio, Hanmi, CHA Bundang Medical Center, Daewoong Pharmaceutical Co., Ltd., Vertical Bio AG<\/b> Grant\/Contract. <br><b>Korea Institute of Oriental Medicine, National Research Foundation of Korea, KHIDI<\/b> Grant\/Contract. <br><b>Abion, BeiGene, Novartis, AstraZeneca, Boehringer-Ingelheim, Roche, BMS, CJ, CureLogen, Cyrus therapeutics, Ono, Onegene Biotechnology,<\/b> Other, Consultant. <br><b>Yuhan, Pfizer, Eli Lilly, GI-Cell, Guardant, HK Inno-N, Imnewrun Biosciences Inc.,  Janssen, Takeda, MSD, Medpacto, Blueprint medicines, RandBio, Hanmi, GC Cell, Gilead, Ridgeline Discovery GmbH<\/b> Other, Consultant. <br><b>Yonsei University Health System<\/b> Employment, Other, Affiliate. <br><b>KANAPH Therapeutic Inc, Bridgebio therapeutics, Cyrus therapeutics, Guardant Health, Oscotec Inc, J INTS Bio, Therapex Co., Ltd, Gilead, Amgen, AstraZeneca, Regeneron, Seagen, Samsung Bioepis<\/b> Other, Advisory Board. <br><b>ASCO, AstraZeneca, Guardant, Roche, ESMO, IASLC, Korean Cancer Association, Korean Society of Medical Onoclogy, Korean Society of Thyroid-Head and Neck Surgery<\/b> Other, Invited Speaker. <br><b>Korean Cancer Study Group, Novartis, MSD, The Chinese Thoracic Oncology Society, Pfizer, Liangyihui Network Technology Co., Ltd.<\/b> Other, Invited Speaker. <br><b>TheraCanVac Inc, Gencurix Inc, Bridgebio therapeutics, KANAPH Therapeutic Inc, Cyrus therapeutics, Interpark Bio Convergence Corp., J INTS BIO<\/b> Stock. <br><b>J INTS BIO<\/b> Other, Member of the Board of Directors. <br><b>DAAN Biotherapeutics<\/b> Other, Founder. <br><b>J. Hilton, <\/b> <br><b>BMS, AstraZeneca, Novartis, Lilly, Merck, Gilead, Seattle Genetics<\/b> Other, Advisory. <br><b>C. P. Rodriguez, <\/b> <br><b>Adaptimmune, Eisai, Vaccitech, Cue Biopharma, Coherus,<\/b> Other, Advisory Role. <br><b>Pionyr<\/b> Other, DSMC.<br><b>M. Bonomi, <\/b> None.&nbsp;<br><b>L. L. Siu, <\/b> <br><b>Merck, Pfizer, AstraZeneca, Roche, GlaxoSmithKline, Voronoi, Arvinas, Navire, Relay, Daiichi Sankyo, Amgen, Marengo, Medicenna, Tubulis, LTZ Therapeutics, Pangea<\/b> Other, Advisory Board. <br><b>Novartis, Bristol-Myers Squibb, Pfizer, Boerhinger-Ingelheim, GlaxoSmithKline, Roche\/Genentech, AstraZeneca, Merck, Celgene, Astellas, Bayer, Abbvie, Amgen, Mirati, BioNTech, 23Me, EMD Serono<\/b> Other, Sponsor\/Funding. <br><b>Agios<\/b> Other, (Spouse) Stocks\/Shares. <br><b>Treadwell Therapeutics<\/b> Other, (Spouse) Ownership Interest. <br><b>M. Gil-Martin, <\/b> <br><b>GSK<\/b> Travel, Other, Speakers Bureau; Scientific meeting expenses. <br><b>MSD<\/b> Travel, Other, Speakers Bureau; Scientific meeting expenses. <br><b>Astra-Zeneca<\/b> Scientific meeting expenses. <br><b>S. Siddiqi, <\/b> <br><b>Merck & Co., Inc<\/b> Employment. <br><b>N. M. Myer, <\/b> <br><b>Merck & Co., Inc<\/b> Employment. <br><b>L. Suttner, <\/b> <br><b>Merck & Co., Inc<\/b> Employment. <br><b>D. Wilson, <\/b> <br><b>Merck & Co., Inc.<\/b> Employment. <br><b>O. Akala, <\/b> <br><b>Merck & Co., Inc.<\/b> Employment. <br><b>R. Dziadziuszko, <\/b> <br><b>Roche<\/b> Other, Invited Speaker, Advisory Board, Principal Investigator, Advisory Role. <br><b>MSD,  Novartis, Bristol-Myers Squibb<\/b> Other, Principal Investigator. <br><b>Pfizer<\/b> Other, Invited Speaker, Advisory Board, Principal Investigator. <br><b>AstraZeneca<\/b> Other, Invited Speaker, Advisory Board, Principal Investigator.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11457","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"21","PosterboardNumber":"22","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT114","PresenterBiography":null,"PresenterDisplayName":"Byoung Chul Cho, MD;PhD","PresenterKey":"a3c74de1-80ab-48ea-8bb1-f1dabd1fc3f1","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT114. Phase 1 study of the anti-immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 plus pembrolizumab in patients with previously untreated advanced head and neck squamous cell carcinoma (HNSCC) or non-small cell lung cancer (NSCLC)","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"610","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase 1 study of the anti-immunoglobulin-like transcript 4 (ILT4) monoclonal antibody MK-4830 plus pembrolizumab in patients with previously untreated advanced head and neck squamous cell carcinoma (HNSCC) or non-small cell lung cancer (NSCLC)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Acute myeloid leukemia,RNA Splicing Mutations,Small molecule inhibitor,Myelodysplastic syndromes,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>H. Yokoyama<\/b><sup>1<\/sup>, N. Fukuhara<sup>2<\/sup>, K. Ando<sup>3<\/sup>, H. Iida<sup>4<\/sup>, T. Yamauchi<sup>5<\/sup>, S. Fukuhara<sup>6<\/sup>, K. Izutsu<sup>6<\/sup>, Y. Tanoue<sup>7<\/sup>, M. Yamamoto<sup>7<\/sup>, H. Tozaki<sup>7<\/sup>, E. Takahara<sup>7<\/sup>, S. Shoji<sup>7<\/sup>, A. Mizutani<sup>7<\/sup>, D. Morishita<sup>7<\/sup>, R. W. Oda<sup>7<\/sup>, H. Miyake<sup>7<\/sup>, N. Yamamoto<sup>6<\/sup>; <br\/><sup>1<\/sup>Yamagata University Hospital, Yamagata, Japan, <sup>2<\/sup>Tohoku University Hospital, Sendai, Japan, <sup>3<\/sup>Atomic Bomb Disease Institute, Nagasaki, Japan, <sup>4<\/sup>NHO Nagoya Medical Center, Nagoya, Japan, <sup>5<\/sup>University of Fukui Hospital, Fukui, Japan, <sup>6<\/sup>National Cancer Center Hospital, Tokyo, Japan, <sup>7<\/sup>Chordia Therapeutics Inc., Kanagawa, Japan","CSlideId":"","ControlKey":"60cd0f70-c5de-4a2b-9a45-ccf462fa1b42","ControlNumber":"9581","DisclosureBlock":"<b>&nbsp;H. Yokoyama, <\/b> <br><b>Astellas<\/b> Other, Honoraria. <br><b>N. Fukuhara, <\/b> <br><b>AbbVie; Bayer; Chugai; Chordia Therapeutics; Genmab; Incyte; Kyowa Kirin; LOXO Oncology; Takeda<\/b> Grant\/Contract. <br><b>AstraZeneca; Bristol Myer Squibb; Chugai; Eisai; Genmab; Janssen; Kyowa Kirin; Meiji Seika Pharma; Nippon Kayaku; Nippon Shiyaku; Novartis; Ono; Symbio; Takeda<\/b> Other, Honoraria. <br><b>Abbvie; AstraZeneca; Eli Lily; HUYA; Novartis<\/b> Other, Board of Directors\/Advisory Board.<br><b>K. Ando, <\/b> None.&nbsp;<br><b>H. Iida, <\/b> <br><b>Chugai; Nippon Kayaku<\/b> Other. <br><b>Chugai; Janssen; Novartis; Sanofi; Takeda<\/b> Other, Honoraria.<br><b>T. Yamauchi, <\/b> None.&nbsp;<br><b>S. Fukuhara, <\/b> <br><b>Chugai; LOXO Oncology; Tanabe Mitsubishi<\/b> Grant\/Contract. <br><b>AbbVie; Amgen; AstraZeneca; Janssen; Ono; Otsuka; Takeda<\/b> Other, Honoraria. <br><b>K. Izutsu, <\/b> <br><b>AbbVie; AstraZeneca; Bristol Myers Squibb; Daiichi-Sankyo; Eisai; Incyte; Janssen; Kyowa Kirin; LOXO Oncology (Eli Lilly); MSD; Novartis; Ono Pharmaceutical; Pfizer; Yakult<\/b> Grant\/Contract. <br><b>AbbVie; AstraZeneca; Bristol Myers Squibb; Genmab; Kyowa Kirin; Mitsubishi Tanabe Pharma; MSD; Nihon Kayaku; Nihon Shinyaku; Ono Pharmaceutical; Zenyaku<\/b> Independent Contractor. <br><b>AbbVie; AstraZeneca; Bristol Myers Squibb; Chugai; Daiichi-Sankyo; Eisai; Eli Lily; Janssen; Kyowa Kirin; MSD; Novartis; Ono Pharmaceutical; Pfizer; Symbio; Takeda<\/b> Other, Honoraria. <br><b>Y. Tanoue, <\/b> <br><b>Chordia Therapeutics<\/b> Employment, Stock Option. <br><b>M. Yamamoto, <\/b> <br><b>Chordia Therapeutics<\/b> Employment, Stock Option. <br><b>H. Tozaki, <\/b> <br><b>Chordia Therapeutics<\/b> Employment, Stock, Stock Option, Patent. <br><b>Honda Motor<\/b> Stock. <br><b>E. Takahara, <\/b> <br><b>Chordia Therapeutics<\/b> Employment. <br><b>S. Shoji, <\/b> <br><b>Chordia Therapeutics<\/b> Employment, Stock Option. <br><b>A. Mizutani, <\/b> <br><b>Chordia Therapeutics<\/b> Employment, Stock, Stock Option. <br><b>D. Morishita, <\/b> <br><b>Chordia Therapeutics<\/b> Employment, Stock, Stock Option, Patent. <br><b>R. W. Oda, <\/b> <br><b>Chordia Therapeutics<\/b> Employment, Stock Option. <br><b>Takeda<\/b> Stock. <br><b>H. Miyake, <\/b> <br><b>Chordia Therapeutics<\/b> Employment, Stock, Stock Option, Other, Representative Director. <br><b>Takeda<\/b> Stock. <br><b>N. Yamamoto, <\/b> <br><b>AbbVie; Astellas; AstraZeneca; Bayer; BMS; Boehringer Ingelheim; Carna Biosciences; Chiome Bioscience; Chugai; CMIC; Daiichi-Sankyo; Eisai; Eli Lilly; Genmab; GlaxoSmithKline; InventisBio<\/b> Grant\/Contract. <br><b>Janssen Pharma; KAKEN; Kyowa Kirin; Merck, MSD; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Rakuten Medical; Shionogi; Sumitomo Pharma; Taiho; Takeda; Toray<\/b> Grant\/Contract.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11458","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"22","PosterboardNumber":"23","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT115","PresenterBiography":null,"PresenterDisplayName":"Hisayuki Yokoyama, MD, PhD","PresenterKey":"840b6dfc-2ed8-4855-9c95-ffa768b57b9e","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT115. A first-in-human phase I study of CTX-712 in patients with advanced, relapsed or refractory malignant tumors (CTX-712-CL-01 study): Efficacy and safety in a hematologic malignancies cohort","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"610","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A first-in-human phase I study of CTX-712 in patients with advanced, relapsed or refractory malignant tumors (CTX-712-CL-01 study): Efficacy and safety in a hematologic malignancies cohort","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Resistance,PIM,KRAS,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"Siqing Fu<sup>1<\/sup>, Rachel E. Sanborn<sup>2<\/sup>, Minxia Cai<sup>3<\/sup>, Lijia Zhang<sup>3<\/sup>, Yanhua Xu<sup>3<\/sup>, <b>Kui Lin<\/b><sup>3<\/sup><br><br\/><sup>1<\/sup>Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX,<sup>2<\/sup>Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR,<sup>3<\/sup>NewBay Pharma, Ningbo, China","CSlideId":"","ControlKey":"0d0bbce1-a566-4927-a520-ad1ab238ce26","ControlNumber":"10732","DisclosureBlock":"<b>&nbsp;S. Fu, <\/b> <br><b>Abbisko; Antengene; BeiGene; BeyongSpring Pharmaceuticals, Inc.; BioAtla, LLC.; Boehringer Ingelheim; CUE Biopharma, Inc.; DEKA Biosciences; Eli Lilly & Co.; Exelixis; Greenfire Bio, Inc.<\/b> Grant\/Contract. <br><b>Hookipa Biotech; IMV, Inc.; Innovent Biologics, Co., Ltd.; Jazz Pharmaceuticlals; K-Group Beta; Lantern Pharma Inc.; Lyvgen Biopharm, Co., Ltd.; MacroGenics; MediLink Therapeutics, Co. Ltd.<\/b> Grant\/Contract. <br><b>Millennium Pharmaceuticals, Inc.; Nerviano Medical Sciences; NeuPharma, Inc.; NextCure, Inc.; Ningbo NewBay Technology Development Co., Ltd.; Novartis; NovoCure; Nykode Therapeutics AS.<\/b> Grant\/Contract. <br><b>Parexel International, LLC; PharmaMar USA, Inc.;  Pionyr Immunotherapeutics, Inc.; PureTech Health, LLC; Qurgen, Inc.; Shanghai Huaota Biopharmaceutical Co., Ltd.;  Sellas Life Sciences Group<\/b> Grant\/Contract. <br><b>Soricimed Biopharma, Inc.; SQZ Biotechnologies; Sumitomo Dainippon; Taiho Oncology and NCCN; Treadwell Therapeutics; Turnstone Biologics; Tyligand Bioscience, Ltd.; Virogin Biotech, Ltd.<\/b> Grant\/Contract. <br><b>R. E. Sanborn, <\/b> <br><b>AstraZeneca<\/b> Grant\/Contract, Other, Consulting fees. <br><b>Merck<\/b> Grant\/Contract. <br><b>GlaxoSmithKline<\/b> Other, Consulting fees. <br><b>Janssen Oncology<\/b> Other, Consulting fees. <br><b>Macrogenics<\/b> Other, Consulting fees. <br><b>Daiichi<\/b> Other, Consulting fees. <br><b>Sanofi<\/b> Consulting fees. <br><b>BeiGene<\/b> Other, Consulting fees. <br><b>Gilead<\/b> Other, Consulting fees. <br><b>Regeneron<\/b> Other, Consulting fees. <br><b>Targeted Oncology<\/b> Other, Consulting fees. <br><b>G1 Therapeutics<\/b> Other, Consulting fees. <br><b>GE HealthCare<\/b> Other, Consulting fees. <br><b>Amgen<\/b> Other, Consulting fees. <br><b>Lilly Oncology<\/b> Other, Consulting fees. <br><b>Ningbo Newbay Technology Development Co., Ltd<\/b> Grant\/Contract. <br><b>M. Cai, <\/b> <br><b>Ningbo NewBay Technology Development Co., Ltd.<\/b> Employment, Stock. <br><b>L. Zhang, <\/b> <br><b>Ningbo NewBay Technology Development Co., Ltd.<\/b> Employment, Stock. <br><b>Y. Xu, <\/b> <br><b>Ningbo NewBay Technology Development Co., Ltd.<\/b> Employment, Stock. <br><b>K. Lin, <\/b> <br><b>Ningbo NewBay Technology Development Co., Ltd.<\/b> Employment, Stock, Patent.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11459","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"23","PosterboardNumber":"24","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT116","PresenterBiography":null,"PresenterDisplayName":"Kui Lin, PhD","PresenterKey":"014959ea-d1ea-4b5f-b3da-eb6a859fff83","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT116. Preclinical antitumor activity and first-in-human phase I study of NB004\/GDC-0570, a novel pan-PIM kinase inhibitor, in patients with advanced solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"610","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Preclinical antitumor activity and first-in-human phase I study of NB004\/GDC-0570, a novel pan-PIM kinase inhibitor, in patients with advanced solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++PL03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"KRAS,Phase I,Small molecule inhibitor,Solid tumors,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>B. Cho<\/b><sup>1<\/sup>, S. Lu<sup>2<\/sup>, M. Lee<sup>3<\/sup>, Z. Song<sup>4<\/sup>, J. Park<sup>5<\/sup>, S. Lim<sup>1<\/sup>, Z. Li<sup>2<\/sup>, J. Zhao<sup>6<\/sup>, G. Richardson<sup>7<\/sup>, Y. Zhang<sup>8<\/sup>, J. Zhang<sup>9<\/sup>, A. Liu<sup>10<\/sup>, C. Chen<sup>11<\/sup>, J. Wang<sup>11<\/sup>, J. Lu<sup>11<\/sup>, H. Rui<sup>11<\/sup>, Q. Chen<sup>11<\/sup>, H. Wang<sup>11<\/sup>, J. Zhang<sup>11<\/sup>, Z. Chen<sup>11<\/sup>, T. Mok<sup>12<\/sup>; <br\/><sup>1<\/sup>Yonsei University Health System, Severance Hospital, Seoul, Korea, Republic of, <sup>2<\/sup>Shanghai Jiao Tong University - Shanghai Chest Hospital, Shanghai, China, <sup>3<\/sup>The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of, <sup>4<\/sup>Zhejiang Cancer Hospital, Jiangsu, China, <sup>5<\/sup>Macquarie University, Syndey, Australia, <sup>6<\/sup>Beijing Cancer Hospital, Beijing, China, <sup>7<\/sup>Cabrini Hospital – Malvern, Melbourne, Australia, <sup>8<\/sup>Harbin Medical University Cancer Hospital, Harbin, China, <sup>9<\/sup>Ruijin Hospital Affiliated to The Shanghai Jiao Tong University Medical School, Shanghai, China, <sup>10<\/sup>The Second Affiliated Hospital of Nanchang University, Jiangxi, China, <sup>11<\/sup>D3 Bio (Wuxi) Co., Ltd., Shanghai, China, <sup>12<\/sup>Chinese University of Hong Kong, Hong Kong, China","CSlideId":"","ControlKey":"ee5a93d1-e2db-4fe8-b011-f53be106bc45","ControlNumber":"9856","DisclosureBlock":"<b>&nbsp;B. Cho, <\/b> <br><b>AstraZeneca, BeiGene, BMS, Boehringer-Ingelheim, BridgeBio Therapeutics, Daichii-Sankyo, Gilead, GSK, Jiangsu Hengrui Medicine, J Ints Bio, Oscotec, Roche, Yuhan<\/b> Other, Research funding. <br><b>AstraZeneca, Boehringer-Ingelheim, BMS, Lilly, Janssen, Takeda, Daiichi-Sankyo, Yuhan, Guardant, Amgen, J Ints Bio<\/b> Served on advisory board meeting.<br><b>S. Lu, <\/b> None..<br><b>M. Lee, <\/b> None..<br><b>Z. Song, <\/b> None..<br><b>J. Park, <\/b> None.&nbsp;<br><b>S. Lim, <\/b> <br><b>AstraZeneca, BeiGene, BMS, Boehringer-Ingelheim, BridgeBio Therapeutics, Daichii-Sankyo, Gilead, GSK, Jiangsu Hengrui Medicine, J Ints Bio, Oscotec, Roche, Yuhan<\/b> Other, Research funding. <br><b>AstraZeneca, Boehringer-Ingelheim, BMS, Lilly, Janssen, Takeda, Daiichi-Sankyo, Yuhan, Guardant, Amgen, J Ints Bio<\/b> Other, Served on advisory board meeting.<br><b>Z. Li, <\/b> None..<br><b>J. Zhao, <\/b> None..<br><b>G. Richardson, <\/b> None..<br><b>Y. Zhang, <\/b> None..<br><b>J. Zhang, <\/b> None..<br><b>A. Liu, <\/b> None.&nbsp;<br><b>C. Chen, <\/b> <br><b>D3 Bio (Wuxi) Co., Ltd.<\/b> Employment. <br><b>J. Wang, <\/b> <br><b>D3 Bio (Wuxi) Co., Ltd.<\/b> Employment. <br><b>J. Lu, <\/b> <br><b>D3 Bio (Wuxi) Co., Ltd.<\/b> Employment. <br><b>H. Rui, <\/b> <br><b>D3 Bio (Wuxi) Co., Ltd.<\/b> Employment. <br><b>Q. Chen, <\/b> <br><b>D3 Bio (Wuxi) Co., Ltd.<\/b> Employment. <br><b>H. Wang, <\/b> <br><b>D3 Bio (Wuxi) Co., Ltd.<\/b> Employment. <br><b>J. Zhang, <\/b> <br><b>D3 Bio (Wuxi) Co., Ltd.<\/b> Employment. <br><b>Z. Chen, <\/b> <br><b>D3 Bio (Wuxi) Co., Ltd.<\/b> Employment. <br><b>T. Mok, <\/b> <br><b>AstraZeneca; BMS; G1 Therapeutics; MSD; Merck Serono; Novartis; Pfizer; Roche; SFJ; Takeda; XCovery<\/b> Grant\/Research Support from:\u000d\u000a(Paid to Institution). <br><b>Abbvie Inc., ACEA Pharma, Adagene, Alpha Biopharma Co., Ltd., Amgen, Amoy Diagnostics Co., Ltd., AstraZeneca (before 1\/1\/19), Bayer Healthcare Pharmaceuticals Ltd., BeiGene, BerGenBio ASA, Berry Onco<\/b> Other, Honoraria\/Honorarium Received \u000d\u000a(for consultation services\/as \u000d\u000aindependent consultant). <br><b>AstraZeneca; Aurora Tele-Oncology Ltd.; Biolidics Ltd.; HutchMed; Prenetics<\/b> Stock. <br><b>Bowtie Life Insurance Co. Ltd.; D3 Bio; Lakeshore Biotech Ltd; Loxo-oncology; Lunit USA, Inc.; Virtus Medical Group<\/b> Stock Option. <br><b>AbbVie Inc., ACEA Pharma, Amgen, AstraZeneca, BerGenBio ASA, Berry Oncology, Blueprint Medicines Corporation, Boehringer Ingelheim, Bowtie Life Insurance Co Ltd, Bristol Myers Squibb, C4 Therapeutics<\/b> Other, Advisory Board. <br><b>AstraZeneca PLC; HutchMed; Aurora<\/b> Other, Board of Directors\/Leadership roles \u000d\u000a(remunerated).","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11460","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"24","PosterboardNumber":"25","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT117","PresenterBiography":null,"PresenterDisplayName":"Byoung Chul Cho, MD;PhD","PresenterKey":"a3c74de1-80ab-48ea-8bb1-f1dabd1fc3f1","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT117. A phase 1 study of D3S-001, a second-generation GDP-bound KRAS G12C inhibitor, as monotherapy in patients with KRAS G12C-mutated solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"610","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"A phase 1 study of D3S-001, a second-generation GDP-bound KRAS G12C inhibitor, as monotherapy in patients with KRAS G12C-mutated solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Cancer,Mesenchymal-epithelial transition (MET),c-Met,Inhibitors,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>T. Song<\/b><sup>1<\/sup>, C. Zhou<sup>2<\/sup>, W. Li<sup>1<\/sup>, X. Li<sup>3<\/sup>, L. Wu<sup>4<\/sup>, S. Zeng<sup>5<\/sup>, L. Miao<sup>6<\/sup>, B. Liu<sup>7<\/sup>, X. Wei<sup>1<\/sup>, J. Chen<sup>1<\/sup>, L. Han<sup>1<\/sup>; <br\/><sup>1<\/sup>Jiangsu Aosaikang Pharmaceutical, Nanjing, China, <sup>2<\/sup>Shanghai Pulmonary Hospital, Shanghai, China, <sup>3<\/sup>The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, <sup>4<\/sup>HuNan Cancer Hospital, ChangSha, China, <sup>5<\/sup>Xiangya Hospital Central South University, Changsha, China, <sup>6<\/sup>Nanjing Drum Tower Hospital, Nanjing, China, <sup>7<\/sup>Tumor Hospital of Harbin Medical University, Harbin, China","CSlideId":"","ControlKey":"a14c5b76-0cfb-4af3-a67c-0796d4e7986b","ControlNumber":"9802","DisclosureBlock":"&nbsp;<b>T. Song, <\/b> None..<br><b>C. Zhou, <\/b> None..<br><b>W. Li, <\/b> None..<br><b>X. Li, <\/b> None..<br><b>L. Wu, <\/b> None..<br><b>S. Zeng, <\/b> None..<br><b>L. Miao, <\/b> None..<br><b>B. Liu, <\/b> None..<br><b>X. Wei, <\/b> None..<br><b>J. Chen, <\/b> None..<br><b>L. Han, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11461","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"25","PosterboardNumber":"26","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT118","PresenterBiography":null,"PresenterDisplayName":"Hong Ma, PhD","PresenterKey":"d0c846a1-c139-4464-97a5-7dcd4e49b2f5","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT118. Phase I dose escalation of ASKC202, a novel cMET tyrosine kinase inhibitor, in patients with advanced solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"610","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase I dose escalation of ASKC202, a novel cMET tyrosine kinase inhibitor, in patients with advanced solid tumors","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++PL03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"NSCLC,KRAS,KRAS G12C inhibitor,targeted therapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>X. Dong<\/b><sup>1<\/sup>, X. Meng<sup>2<\/sup>, Y. Zhang<sup>2<\/sup>, Y. Wang<sup>3<\/sup>, J. Chen<sup>4<\/sup>, L. Han<sup>5<\/sup>, Q. Wang<sup>6<\/sup>, Z. Lin<sup>7<\/sup>, H. Wei<sup>8<\/sup>, S. Lin<sup>9<\/sup>, C. Li<sup>10<\/sup>, Q. Wu<sup>8<\/sup>; <br\/><sup>1<\/sup>Huazhong University of Science and Technology, Wuhan, China, <sup>2<\/sup>Affiliated Cancer Hospital of Shandong First Medical University, JiNan, China, <sup>3<\/sup>Harbin Medical University Affiliated Cancer Hospital, Harbin, China, <sup>4<\/sup>Hunan Cancer Hospital\/Cancer Hospital Affiliated to Central South University, Changsha, China, <sup>5<\/sup>Department of Oncology Xuzhou Central Hospital, Xuzhou, China, <sup>6<\/sup>Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University, zhengzhou, China, <sup>7<\/sup>The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China, <sup>8<\/sup>Department of Oncology Medicine, Hansoh Pharma Group CO.,LTD, Shanghai, China, <sup>9<\/sup>Department of Oncology Medicine, Hansoh Pharma Group CO.,LTD, Shanghai, China, Shanghai, China, <sup>10<\/sup>Department of Medical Oncology , Hansoh Pharma Group CO.,LTD, Shanghai, China","CSlideId":"","ControlKey":"12e9f65d-ad16-432b-afbf-260b744ab4cc","ControlNumber":"10336","DisclosureBlock":"<b>&nbsp;X. Dong, <\/b> <br><b>Hansoh Pharma Group CO.,LTD<\/b> Other, I am a researcher funded by the company&#65288;Hansoh Pharma Group CO.,LTD&#65289;\u000d\u000a\u000d\u000a. <br><b>X. Meng, <\/b> <br><b>Hansoh Pharma Group CO.,LTD<\/b> Other, I am a researcher funded by the company&#65288;Hansoh Pharma Group CO.,LTD. <br><b>Y. Zhang, <\/b> <br><b>Hansoh Pharma Group CO.,LTD<\/b> Other, I am a researcher funded by the company &#65288;Hansoh Pharma Group CO.,LTD&#65289;. <br><b>Y. Wang, <\/b> <br><b>Hansoh Pharma Group CO.,LTD<\/b> Other, I am a researcher funded by the company &#65288;Hansoh Pharma Group CO.,LTD&#65289;. <br><b>J. Chen, <\/b> <br><b>Hansoh Pharma Group CO.,LTD<\/b> Other, I am a researcher funded by the company &#65288;Hansoh Pharma Group CO.,LTD&#65289;. <br><b>L. Han, <\/b> <br><b>Hansoh Pharma Group CO.,LTD<\/b> Other, I am a researcher funded by the company &#65288;Hansoh Pharma Group CO., LTD&#65289;. <br><b>Q. Wang, <\/b> <br><b>Hansoh Pharma Group CO., LTD<\/b> Other, I am a researcher funded by the company &#65288;Hansoh Pharma Group CO., LTD&#65289;. <br><b>Z. Lin, <\/b> <br><b>Hansoh Pharma Group CO., LTD<\/b> Other, I am a researcher funded by the company &#65288;Hansoh Pharma Group CO., LTD&#65289;. <br><b>H. Wei, <\/b> <br><b>Hansoh Pharma Group CO.,LTD,<\/b> Employment. <br><b>S. Lin, <\/b> <br><b>Hansoh Pharma Group CO.,LTD,<\/b> Employment. <br><b>C. Li, <\/b> <br><b>Hansoh Pharma Group CO.,LTD,<\/b> Employment. <br><b>Q. Wu, <\/b> <br><b>Hansoh Pharma Group CO.,LTD,<\/b> Employment.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11462","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"26","PosterboardNumber":"27","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT119","PresenterBiography":null,"PresenterDisplayName":"Xiaorong Dong, PhD","PresenterKey":"b26f2cb5-edca-4f2b-aeb6-3f9ce570f5d1","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT119. Safety and efficacy of HS-10370 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC)","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"610","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Safety and efficacy of HS-10370 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC)","Topics":null,"cSlideId":""},{"Abstract":"Abstract is embargoed at this time.","Actions":[{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Late Breaking and Clinical Trials","AdditionalFields":[{"Key":"Topics","Value":"++CT03-01 First-in-human phase I trials,,"},{"Key":"Keywords","Value":"Cell death,First-in-human,Clinical trial,Combination antineoplastic therapy,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":null,"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>A. L. De Souza<\/b><sup>1<\/sup>, N. Takebe<sup>1<\/sup>, A. P. Chen<sup>1<\/sup>, J. H. Doroshow<sup>1<\/sup>, R. E. Parchment<sup>2<\/sup>, A. K. Srivastava<sup>2<\/sup>, L. Rubistein<sup>1<\/sup>, D. Wilsker<sup>2<\/sup>, B. L. Miller<sup>2<\/sup>, M. Hogu<sup>1<\/sup>, G. O. Coney<sup>3<\/sup>, S. Kummar<sup>4<\/sup>, J. Govindharajulu<sup>2<\/sup>, R. Meehan<sup>1<\/sup>, W. G. Herrick<sup>2<\/sup>, A. Dull<sup>2<\/sup>, D. Ketchum<sup>2<\/sup>, S. Li<sup>2<\/sup>, J. Ji<sup>2<\/sup>, R. Piekarz<sup>1<\/sup>; <br\/><sup>1<\/sup>National Cancer Inst. - Bethesda Campus, Bethesda, MD, <sup>2<\/sup>Frederick National Laboratory for Cancer Research, NCI at Frederick, Frederick, MD, <sup>3<\/sup>Mater Misecordiae University Hospital, Dublin, Ireland, <sup>4<\/sup>OHSU Knight Cancer Institute, School of Medicine, Portland, OR","CSlideId":"","ControlKey":"eddaf33d-ad3d-4f7f-9aae-0ad3147117e0","ControlNumber":"10470","DisclosureBlock":"&nbsp;<b>A. L. De Souza, <\/b> None..<br><b>N. Takebe, <\/b> None.&nbsp;<br><b>A. P. Chen, <\/b> <br><b>Genentech<\/b> The National Cancer Institute has Cooperative Research and Development Agreements (CRADAs) with Genentech and AZ. These CRADAs provide resources for co-development of experimental agents.. <br><b>AZ<\/b> The National Cancer Institute has Cooperative Research and Development Agreements (CRADAs) with Genentech and AZ. These CRADAs provide resources for co-development of experimental agents..<br><b>J. H. Doroshow, <\/b> None..<br><b>R. E. Parchment, <\/b> None..<br><b>A. K. Srivastava, <\/b> None..<br><b>L. Rubistein, <\/b> None..<br><b>D. Wilsker, <\/b> None..<br><b>B. L. Miller, <\/b> None..<br><b>M. Hogu, <\/b> None..<br><b>G. O. Coney, <\/b> None..<br><b>S. Kummar, <\/b> None..<br><b>J. Govindharajulu, <\/b> None.&nbsp;<br><b>R. Meehan, <\/b> <br><b>Moderna<\/b> Employment.<br><b>W. G. Herrick, <\/b> None..<br><b>A. Dull, <\/b> None..<br><b>D. Ketchum, <\/b> None..<br><b>S. Li, <\/b> None..<br><b>J. Ji, <\/b> None..<br><b>R. Piekarz, <\/b> None.","End":"4\/8\/2024 5:00:00 PM","HasWebcast":null,"Highlights":[],"Id":"11678","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":null,"OtherContent":null,"PlayerUrl":"https:\/\/files.abstractsonline.com\/SUPT\/101\/10517\/cfg-cattendee-cslide-player-view-content-embargoed.png","PlayerUrlReason":"Content is embargoed at this time.","PositionInSession":"27","PosterboardNumber":"28","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"CT120","PresenterBiography":null,"PresenterDisplayName":"Andre De Souza, MD","PresenterKey":"24215863-4843-43d6-b71e-58ab76974dfd","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"CT120. Phase 1 trial of bortezomib and clofarabine combination in adults with refractory solid tumors","SearchResultFooter":"","SearchResultHeader":"Apr  8 2024  1:30PM","SessionId":"610","SessionOnDemand":"False","SessionTitle":"First-in-Human Phase I Clinical Trials 1","ShowChatLink":"false","Start":"4\/8\/2024 1:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Phase 1 trial of bortezomib and clofarabine combination in adults with refractory solid tumors","Topics":null,"cSlideId":""}]